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1. Summary 
The Notch signaling pathway is an evolutionary conserved pathway that plays essential 
roles during vascular development and in the regulation of normal and pathological 
angiogenesis in the adulthood. These roles include angioblast specification, 
arteriovenous differentiation, regulation of blood vessel sprouting and branching, as well 
as control of vessel maintenance. In mammals there are four Notch receptors (Notch1 – 
4), but only Notch1 and Notch4 are expressed in endothelial cells. Endothelial-specific 
loss of Notch1 is embryonic lethal, demonstrating its pivotal function in the vascular 
system. Nevertheless, the role of Notch1 signaling in postnatal vascular physiology is not 
fully understood. Inducible deletion of Notch1 in mice has been shown to cause nodular 
regenerative hyperplasia (NRH), which is a histopathological entity of the liver also seen 
in humans. NRH is thought to appear secondary to microcirculatory disturbances, 
however the exact pathogenesis is not known. NRH is an important cause of non-cirrhotic 
portal hypertension. The increased portal pressure can lead to complications including 
splenomegaly, ascites, or variceal bleeding; the latter is associated with high mortality. 
The aim of this thesis is to elucidate the role of Notch1 signaling in the hepatic 
microcirculation in normal and pathologic conditions. Further, we want to shed some light 
on the molecular mechanisms implicated in the development of NRH. 
 
In a conditional Notch1 knockout (KO) mouse model we investigated the impact of 
Notch1 signaling deficiency on the blood vessel homeostasis in the liver. LSEC are 
normally quiescent. After observing LSEC activation in livers of Notch1 KO mice, resulting 
in increased cell proliferation, we wanted to explore the ultrastructure of sinusoids in more 
detail. Scanning electron microscopy analysis of the liver microvasculature revealed 
phenotypic changes of LSEC, identified by loss of fenestrae. By performing vascular 
casts, we could discover three-dimensional changes of the hepatic microvasculature. 
While livers of control mice showed a highly differentiated vascular network, the liver 
vasculature of Notch1 KO mice was remodeled showing increased branching with larger 
vessel diameters. In addition, we identified features of intussusceptive angiogenesis in 
Notch1 KO casts. Time course experiments revealed that vascular changes occur first 
and that development of portal hypertension and NRH is a secondary phenomenon. To 
exclude that the observed phenotypic changes are due to loss of Notch1 in cells other 
than LSEC, a hepatocyte-specific Notch1 KO mouse was generated. This mouse had a 
completely normal phenotype. Furthermore, different cell populations were isolated from 
global Notch1 KO mice. Gene expression analysis of the different cell types confirmed 
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that loss of Notch1 mainly affects the endothelium. Vascular dedifferentiation was found 
to be mediated by Notch, ephrin, and TEK signaling, all of which are known to regulate 
LSEC differentiation and quiescence. A very crucial finding, supporting our hypothesis 
that the NRH phenotype is driven by vascular changes, is the spontaneous development 
of liver angiosarcoma in Notch1 KO mice. Disruption of Notch1 signaling is sufficient 
enough to induce malignant transformation of endothelial cells in the liver, reflecting the 
pivotal role of Notch1 in the hepatic microcirculation. 
 
In a translational study using liver biopsies from NRH patients we assessed the vascular 
contribution to the development of NRH. Using morphological and molecular approaches, 
this part of the thesis addressed two main questions: one from a clinical point of view, the 
other from a basic science perspective. 
First, we assessed whether there is an association between the presence of portal 
hypertension and NRH severity. So far, no one has investigated the relationship between 
pathologic features and the clinical condition in NRH. Notably, histological assessed 
nodular transformation correlates well with the presence of portal hypertension. Since 
most complications occurring in NRH patients are due to increased portal pressure, 
patients presenting with advanced nodular transformation should be advised to undergo 
endoscopic screening for varices, since they can cause life-threatening complications. 
Based on our findings from the animal study we have hypothesized that NRH is caused 
by a vascular injury of the sinusoids. In our NRH mouse model we identified dysregulation 
of a number of genes upon Notch1 deletion, which are involved in endothelial 
differentiation. Therefore, we wanted to explore if the same set of genes is also regulated 
in human NRH. To our surprise, the same genes were also found to be dysregulated in 
the liver of NRH patients, irrespective of the underlying cause of disease. Thus we 
conclude: Despite different etiologic factors associated with NRH, there is evidence that 
in all cases the hepatic condition can be traced back to an endotheliopathy mediated by 
the final common pathway of Notch1/Dll4 and EphrinB2/EphB4 signaling. 
 
Taken together, our study identifies Notch1 as an important player in LSEC differentiation 
and quiescence. We provide first insights into the molecular mechanism of human NRH, 
which are in line with our findings from the NRH mouse model. In addition, we showed an 
oncosuppressive role of Notch1 in the murine liver endothelium, resulting in vascular 
neoplasms after loss of Notch1. 
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2. Abbreviations 
Ac-LDL  acetylated low–density lipoprotein 
ADAM   a distintegrin and metalloprotease 
AGS   Alagille syndrom 
AlbCre   albumin Cre 
alpha-SMA  alpha smooth muscle actin 
ALT   alanine aminotransferase 
Ang   angiopoietin 
AST aspartate aminotransferase 
BRDU 5-bromo-2’-deoxyuridine 
CADASIL cerebral autosomal dominant arteriopathy with subcortical infarcts 
and leukoencephalopathy 
CSL   CBF-1/Suppressor of Hairless/Lag-1 
DAPT N-[(3,5-Difluorophenyl)acetyl]-L-alanyl-2-phenyl]glycin e-1,1-
dimethylethyl ester 
Dll   delta like 
DNA   deoxyribonucleic acid 
EC   endothelial cell 
ECM   endothelial cell medium 
Efnb2   EphrinB2 
EGFR   epidermal growth factor receptor 
eNOS   endothelial nitric oxide synthase 
EPC   endothelial precursor cell (angiogblast) 
Ephb4   Ephrin receptor B4 
FGF   fibroblast growth factor 
Flk   fetal liver kinase 
Flt    fms related tyrosin kinase 
FNH   focal nodular hyperplasia 
GGT   gamma glutamyl transferase 
GOM   granular osmophilic material 
GSI   gamma-secretase inhibitor 
HCC   hepatocellular cancer 
HCV   hepatitis C virus 
Hes   hairy-and-enhancer-of-split 
Hey   hairy-and-enhancer-of-split related 
HGF   hepatocyte growth factor 
HIF   Hypoxia inducible factor 
HPF   high power field 
HSC   hepatic stellate cells 
HVPG   hepatic venous pressure gradient 
INR   international normalized ratio 
KO   knockout 
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LDL   low density lipoprotein 
LSEC   liver sinusoidal endothelial cells 
MAML   mammalian Mastermind-like 
MELD   model for end stage liver disease 
MHC   major histocompatibility complex 
MMP   matrix metalloproteinase 
MMTV   mouse mammary tumor virus 
mRNA   messenger RNA 
NCPH   non-cirrhotic portal hypertension 
NICD   notch intracellular domain 
NO   nitric oxide 
NRH   nodular regenerative hyperplasia 
PBS   phosphate-buffered saline 
PCR   polymerase chain reaction 
PDGF   platelet-derived growth factor 
PDGFR  platelet-derived growth factor receptor 
PHx   partial hepatectomy 
PlGF   placenta growth factor 
qPCR   quantitative PCR 
RBPJ   recombination signal-binding protein-Jκ 
RT-PCR  reverse-transcription PCR 
S   site 
SEM   scanning electron microscopy 
Shh   sonic hedgehog 
SMC   smooth muscle cells 
SOS   sinusoidal obstruction syndrome 
T-ALL   T-cell acute lymphoblastic leukemia 
TEK/Tie  tyrosine kinase with immunoglobulin-like and EGF-like domains 
TGF   transforming growth factor 
VE-cadherin  vascular endothelial cadherin 
VEGF   vascular endothelial growth factor 
VEGFR  vascular endothelial growth factor receptor 
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3. Introduction 
3.1 Liver vasculature 
3.1.1 The hepatic circulation 	
  
The liver is the largest internal organ and its complex microcirculation is required for the 
important liver functions in biosynthesis, metabolism, clearance, and immune response 
[1].  
The liver receives a dual blood supply. Approximately 80% of the blood is received from 
the portal vein, the remaining 20% are delivered by the hepatic artery. While the portal 
vein conducts poorly oxygenated, nutrient-rich blood from digestive organs to the liver, 
the hepatic artery delivers well-oxygenated blood [2]. The portal vein and hepatic artery 
are further subdivided into the terminal branches, portal venules and hepatic arterioles, 
which eventually drain into the sinusoids where portal and arterial blood gets mixed. The 
sinusoids represent the capillary network of the liver and transport the blood from 
periportal to centrilobular regions in the liver (Figure 1). After perfusion of the liver 
parenchyma, the blood is collected in terminal hepatic venules, the hepatic vein and 
finally the inferior vena cava and right atrium [2,3]. 
 
 
Figure1. Microanatomy of the hepatic lobule. The liver receives 
blood from the portal vein and the hepatic artery, both draining into 
sinusoids, which represent the capillary network in the liver (from [4]). 
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3.1.2 The hepatic sinusoids and sinusoidal endothelial cells 	
  
Hepatocytes (parenchymal cells) comprise 80% of the liver mass, whereas the other 20% 
are represented by non-parenchymal cells mainly including sinusoidal endothelial cells, 
Kupffer cells (the resident macrophages of the liver), hepatic stellate cells (the hepatic 
equivalent to pericytes), and liver-associated lymphocytes [3,5]. The hepatic circulation is 
predominantly lined by liver sinusoidal endothelial cells (LSEC), which account for 50% of 
the non-parenchymal cells [3]. To stabilize the vascular structures, extraluminal hepatic 
stellate cells (HSC) enwrap the sinusoids. They are located within the perisinusoidal 
space of Disse, which is the separating space between endothelial cells and hepatocytes.   
LSEC possess specific morphologic features to exert the repertoire of their liver specific 
functions. Presence of fenestrae, which are pores in the cell supported by cytoskeleton 
and the lack of a basal lamina characterize this unique LSEC phenotype, distinguishing 
them from other endothelial cells [3]. Thus, LSEC are a prime example of phenotypic 
heterogeneity of the endothelium. Non-diaphragmed fenestrae with diameters around 100 
– 200 nm are grouped together in so-called “sieve plates” [6,7]. Sieve plates encompass 
20 - 50 pores and have a diameter of around 0.1 µm [3]. Distribution and size of 
fenestrae in the sinusoidal endothelium is not uniform. Depending on the intralobular 
localization they occupy 6% to 8% of the endothelial surface [2,8]. An actin containing 
cytoskeleton forms and supports fenestrae and sieve-plates [9,10]. Fenestrae are 
dynamic structures, which are actively regulated by the fenestrae-associated 
cytoskeleton. As a result, regulation of endothelial permeability controls the important 
hepatic function of endothelial filtration. Because of the absence of a basement 
membrane the endothelium acts as a selective barrier. Thus, the diameter and frequency 
of sinusoidal fenestrations directly determines the exchange between blood and hepatic 
parenchyma [8,9]. Chylomicrons, which have a size between 100 - 1000 nm, are not able 
to leave the sinusoids, while the smaller chylomicron-remnants, 30 - 80 nm in size, are 
filtered through the sinusoidal fenestrae to enter the space of Disse. It is now well 
established that the “liver sieve” influences the lipoprotein metabolism and consistent with 
the fact that chylomicron-remnants are the most artherogenic circulating lipoproteins, 
fenestrae have an important role in the pathogenesis of artherosclerosis [8,9,11]. Two 
mechanisms have been described to increase the diameter of fenestrae: disruption of the 
actin-containing components of the cytoskeleton or application of vascular endothelial 
growth factor (VEGF) [9,12–14]. Active investigations within the last years brought up an 
increasing list of agents, which alter the number and diameter of fenestrae. Hormones 
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like adrenalin or serotonin, drugs such as acetylcholine, toxins like ethanol, but also 
diseases and aging manipulate the fenestration pattern of LSEC [6]. 
Another physiological role attributed to LSEC is their scavenger function. The presence of 
numerous endocytic vesicles in LSEC evinces their high endocytic activity [15]. To clear a 
multitude of physiological and foreign macromolecules and colloids from the blood, LSEC 
are specialized in receptor-mediated endocytosis. LSEC display an array of endocytosis 
receptors at their cell membrane by which they take up a wide range of substances. 
Among these receptors, the mannose receptor and scavenger receptor are found in 
LSEC but also in Kupffer cells, demonstrating the complementary function of these two 
cell types in blood clearance [16,17]. Acetylated low–density lipoprotein (Ac-LDL), whose 
uptake is mediated through the scavenger receptor, is mainly sequestered by LSEC 
when compared to Kupffer cells. However, endocytosis of Ac-LDL is not a suitable 
functional marker for LSEC since extrahepatic endothelial cells also have been reported 
to endocytose Ac-LDL [16,18,19]. Recently, new members of the scavenger receptor 
family were found to be expressed exclusively on LSEC. These are stabilin-2 and 
lymphatic vessel endothelial hyaluronan receptor [19]. 
The participation of the liver in immunity is well accepted. One aspect that favors a 
contribution to the immune system is the excellent strategic position in the portal 
circulation as well as the large surface area of LSEC. The organ is supplied with blood 
from the gastrointestinal tract via the portal vein and with systemic blood delivered by the 
hepatic artery. Thus, the liver is constantly exposed to antigens and microbial products 
and unnecessary activation of the immune system needs to be prevented. LSEC, as the 
sinusoidal lining cells, are therefore in direct contact with antigens but also with 
lymphocytes. In the liver, antigen clearance from the blood is mainly performed by LSEC 
via scavenger-receptor mediated uptake [17]. LSEC interact directly with circulating 
lymphocytes, such as CD4 T and CD8 T cells. Moreover, LSEC constitutively express 
molecules for antigen presentation, major histocompatibility complex (MHC) class I and II, 
and co-stimulatory molecules (CD40, CD80, CD86), which allow LESC to function as 
antigen-presenting cells [20]. Antigen presentation via MHC class II to naïve CD4 T cells 
induces a regulatory phenotype (Treg) [21]. In addition, LSEC induce CD8 T cell tolerance 
by cross-presentation of exogenous antigens presented on MHC class I molecules. [22] 
Usually cross-presentation is restricted to myeloid cells [20]. In contrast to CD8 T cells 
primed by matured dendritic cells, which acquire a cytotoxic activity, LSEC primed CD8 T 
cells lack effector functions and lead to tolerance induction rather than enhanced 
immunity [23]. Interestingly, LSEC induced T cell tolerance is shifted to T cell 
differentiation into effector cells after viral infection of LSEC [23]. The tolerogenic effect of 
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LESC is consistent with the phenomenon of liver allograft-induced T cell tolerance, which 
reduces the event of organ rejection [24]. Another example highlighting the immune 
function of the liver is the loss of tolerance combined with enhanced generation of 
antibodies recognizing intestinal bacterial antigens after portosystemic shunting, a 
situation in which blood from the intestines reaches the systemic circulation without 
traversing the liver, the main site for metabolism and detoxification [3]. 
  
3.1.3 Liver sinusoidal endothelial cells in vascular liver disease 	
  
While injury of the liver parenchyma can cause chronic liver diseases subsequently 
leading to vascular remodeling, as it is the case in liver cirrhosis, the opposite scenario is 
also possible. A number of liver diseases originate in the endothelium with a vascular 
injury being the cause for hepatic changes. LSEC are an early target of toxins, therefore 
sinusoidal injury is involved in a number of vascular liver diseases such as sinusoidal 
obstruction syndrome (SOS), fibrosis, ischemia-reperfusion injury, peliosis hepatis, and 
nodular regenerative hyperplasia [25]. Vascular damage can occur in the large blood 
vessels of the liver, as observed in portal vein thrombosis or Budd-Chiari syndrome. 
Otherwise, endotheliopathy can also be ascribed to the microvasculature with the 
consequence of SOS or NRH. 
 
3.1.3.1 Sinusoidal obstruction syndrome 	
  
Sinusoidal obstruction syndrome used to be named hepatic veno-occlusive disease. After 
experimental evidence proofed that central vein occlusion is not essential for the 
development of SOS, the name was changed. Because of the finding that this disease is 
caused by a circulatory damage at the level of the sinusoids, the term SOS is more 
appropriate than the old name [26]. SOS can be induced by ingestion of pyrrolizidine 
alkaloids or due to specific drugs (i.e. Gemtuzumab ozogamicin; Mylotarg®) alone or in 
combination with irradiation. While pyrrolizidine alkaloid-induced SOS is mainly found in 
non-Western nations, SOS in North America and Western Europe is most commonly 
caused by myeloablative regimens. These regimens are a combination of high-dose 
chemotherapy drugs or chemotherapy plus irradiation therapy [26,27]. The primary event 
in SOS is a toxic insult to the sinusoidal endothelium leading to circulatory obstruction 
with subsequent liver dysfunction [28]. Studies in the experimental monocrotaline rat 
model of SOS yielded insights into the pathophysiology of this disease. The cytochrome 
P450-activated monocrotaline metabolite depolymerizes F-actin, which is the structural 
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component of the LSEC skeleton [29]. Upon actin depolymerization matrix 
metalloproteinase-9 (MMP-9) gets activated. MMP-9 is an enzyme that digests 
extracellular matrix tetherings of LSEC with the consequence that cells start to round up, 
which in turn leads to gaps in the endothelial barrier [30]. The red blood cells are then 
able to penetrate into the space of Disse, where they dissect the sinusoidal endothelial 
lining away from the parenchymal cells. Sinusoidal cells embolize downstream, 
obstructing the sinusoidal blood flow [28]. Protecting LSEC by the administration of 
sinusoidal cell glutathation is able to prevent SOS [28,31]. This finding further underlines 
the primary role of LSEC in the pathogenesis of SOS. 
Furthermore, Wang and colleagues showed that conditional knockout of recombination 
signal-binding protein-Jκ (RBP-J), which is the Notch signaling mediating transcription 
factor, leads to LSEC proliferation and SOS-like pathological changes presented by 
significant liver congestion, deposition of fibrin-like materials in hepatic sinusoids, and 
edema in the space of Disse [32]. 
 
3.1.3.2 Liver Fibrosis 	
  
Liver injury results in wound healing with accumulation of extracellular matrix, a process 
referred to as hepatic fibrosis.  Liver fibrosis is reversible if the insult is acute. However, in 
case of sustained, chronic injury progressive accumulation of scarring tissue replaces 
normal liver tissue and advanced hepatic fibrosis eventually leads to liver cirrhosis. 
Deposition of extracellular matrix stimulates hepatocyte regeneration followed by 
distortion of the hepatic parenchyma and the vascular architecture. These pathological 
changes are known to activate angiogenic stimuli. 
Numerous investigators explored the relationship between angiogenesis and fibrogenesis 
in chronic liver diseases and it has been shown that the two processes go hand in hand. 
Two pathways are implicated in the fibrogenic process. First, fibrogenesis and 
angiogenesis occur in response to chronic wound healing activated by an up-regulation of 
growth factors, cytokines, metalloproteinases, and molecules involved in extra-cellular 
matrix remodeling [33,34]. Secondary to the increased tissue hypoxia, which results from 
progressive sinusoidal capillarization amongst other possible causes, pro-angiogenic 
pathways are switched on [26,35]. 
Differentiated LSEC maintain hepatic stellate cells quiescent through VEGF-induced nitric 
oxide (NO) synthesis and they are even able to promote reversion of activated HSC to 
quiescence [36]. Stellate cell activation into a proliferative, contractile and fibrogenic cell 
is a key event in fibrogenesis. Formation of extracellular matrix by activated HSC is the 
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major mechanism inducing hepatic fibrosis, whereas contractile activity of HSC further 
increases the intrahepatic vascular tone [37]. Capillarized LSEC, which underwent a 
dedifferentiation towards a vascular phenotype, lack the property to prevent stellate cell 
activation because VEGF stimulation of NO production is lost [36]. Interestingly, restoring 
of LSEC differentiation in capillarized livers induces quiescence of HSC and regression of 
fibrosis in experimental models. Hence, LSEC differentiation seems to be the central 
determinant in progression of fibrosis [38]. 
The two key features of LSEC phenotype are non-diaphragmed fenestrae and absence of 
a basement membrane. Paracrine VEGF secretion by hepatocytes or HSC, inducing an 
autocrine production of NO by endothelial nitric oxide synthase (eNOS) in LSEC, is 
required to maintain LSEC differentiation [39]. Loss of fenestration with development of a 
continuous basement membrane is termed “capillarization”. In the aging liver a mitigated 
version called “pseudocapillarization” occurs [40]. These ultrastructural changes of LSEC 
leading to capillarization impede the exchange between sinusoidal blood and 
parenchymal cells and cause a mechanical increase of the sinusoidal vascular resistance 
[41,42]. Capillarization precedes fibrosis in a variety of chronic liver diseases, such as 
alcoholic liver injury and non-alcoholic fatty liver disease [43–45]. Dedifferentiation of 
LSEC towards a vascular phenotype, observed in all forms of cirrhosis, impairs hepatic 
functions and seems to be the initial trigger of this chronic liver disease. Further, 
capillarization is involved in atherosclerosis and contributes to age-related dyslipidemia 
[6,11,40]. CD31 (also known as platelet endothelial cell adhesion molecule-1; PECAM-1) 
has been identified as a marker of capillarization. In normal liver, sinusoidal EC lack 
expression of CD31 as well as CD34. During the process of sinusoidal capillarization 
occurring in cirrhosis, the structural changes of LSEC go along with striking changes in 
the expression pattern of cell-adhesion molecules, including upregulation of CD31 
expression on the protein and messenger-RNA level [39,46,47]. In addition, CD31 
surface expression correlates inversely with fenestration [39]. 
 
3.1.3.3 Non-cirrhotic portal hypertension 	
  
In the Western world portal hypertension is the main complication of cirrhosis [48]. 
However, increased portal pressure is also seen in the absence of hepatic cirrhosis or of 
chronic liver conditions associated with cirrhosis. This condition is referred to as non-
cirrhotic portal hypertension (NCPH) [49]. Portal hypertension is a clinical syndrome 
defined by an increase in the portal pressure gradient between the portal vein and the 
inferior vena cava [42]. While normal values range from 1 to 5 mm Hg, increased portal 
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pressure becomes clinically relevant if values increase to 10 mm Hg or above [42]. NCPH 
is the collective term for a variety of pathological liver lesions, which were recently 
classified into four subcategories: idiopathic portal hypertension, diffuse nodular 
regenerative hyperplasia (see below), partial nodular transformation, and incomplete 
septal cirrhosis [50]. Differential diagnosis of these lesions is challenging and patients 
often present more than one of the morphologic alterations. Probably the lesional 
spectrum is caused by a shared etiology, which is irregular perfusion of the liver. Causes 
of NCPH can be divided into five categories: immunological disorders, infections, 
medication or toxins, genetic diseases, and thrombophilia [51]. The pathophysiology of 
NCPH still remains controversial. Schouten et al. hypothesized that two mechanisms are 
involved in the development of NCPH. Increased splenic blood flow, caused by elevated 
NO release in the sinus-lining cells of the spleen, is one mechanism leading to NCPH. 
The other factor playing a role in NCPH is an increase in intrahepatic resistance resulting 
from portal venous obliterations. Circulatory lesions due to thrombophilia, immunological 
disorders, infections, and medication possibly induce portal venous obliteration [51]. The 
main clinical manifestations are related to complications of portal hypertension, such as 
variceal bleeding, splenomegaly, and ascites [51]. Liver function generally is preserved 
and the prognosis depends on the underlying pathologic conditions [49]. Treatment of 
NCPH patients is focused on complications of portal hypertension as well as on the cure 
of the initiating hepatic disorder. 
 
3.1.3.4 Nodular regenerative hyperplasia 	
  
Nodular regenerative hyperplasia is a rare liver disease characterized by the 
transformation of hepatic parenchyma into small regenerative nodules accompanied by 
no or only little fibrosis. Steiner was the first one describing this hepatic lesion with 
alternating areas of regeneration and atrophy lacking fibrous bands, scars, or septa, 
clearly distinguishing this condition from cirrhosis [52]. A large autopsy study by Wanless 
found NRH to occur at an incidence of 2.6%. In the same study, Wanless proposed a 
classification for nodular transformation: micronodular transformation corresponds to 
parenchymal nodules smaller than 3 mm in diameter in the absence of fibrous tissue. 
Nodularity was graded 0 to 3+ depending on their distinct appearance. Presence of 
fibrous septa was also graded ranging from 0 to 3. To meet the diagnosis of NRH, the 
hepatic lesions had to comply with grade 3 nodular transformation and grade 0 to 1 
fibrous septa [53]. The pathogenesis of NRH seems to be related to hemodynamic 
disturbances in the liver microvasculature. Impaired portal venous blood flow leads to 
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hepatocyte atrophy, whereas regenerative nodules express the hyperplastic reaction of 
hepatocytes induced by maintained or increased blood supply [53–55]. The first 
hypothesis on the pathogenetic mechanism of NRH was proposed by Wanless et al. 
suggesting that obliterative vascular lesions cause local ischemia, which then induce 
atrophy and consequently regenerative nodule formation [54]. This etiologic concept has 
matured within the last decades and it is now accepted that circulatory impairment is the 
response to a vascular lesion on the sinusoidal level [26,56]. NRH has been described in 
the setting of several systemic diseases including hematologic disorders, autoimmune 
diseases, and vascular disorders, as well as in association with certain drugs [57]. Liver 
function is generally preserved in patients with NRH; accordingly the course of disease is 
indolent in most patients. The most common manifestation of NRH is non-cirrhotic portal 
hypertension [49,57,58]. Although NRH usually evolves without symptoms, some patients 
become symptomatic with a clinical picture that is dominated by portal hypertension and 
its complications such as gastroesophageal varices, splenomegaly and ascites [57]. 
Management of NRH patients is aimed to eliminate the underlying causes and to treat the 
sequelae of the resultant portal hypertension.  
 
3.2 Angiogenesis 
3.2.1 Mechanisms of vascular development 	
  
The vascular system is one of the first organs that develops during embryogenesis 
because oxygen and nutrient supply is mandatory to assure further development of the 
organism [59]. Blood vessel formation and remodeling involves three distinct 
mechanisms: vasculogenesis, angiogenesis, and arteriogenesis (Figure 2). De novo 
blood vessel formation, named vasculogenesis, refers to differentiation of mesoderm-
derived angioblasts into endothelial cells, which then coalesce to generate the primary 
vascular plexus [60]. Angiogenesis, defined as new blood vessel formation from pre-
existing vessels, expands the primitive vascular network by sprouting and non-sprouting 
(intussusceptive) angiogenesis. During arteriogenesis the arterial lumen is increased and 
mural cells (pericytes in the microvasculature and smooth muscle cells in arteries and 
veins) are recruited to stabilize the nascent vessels [61–63]. Finally a mature hierarchical 
circulatory system is established. The formation of such a complex network relies on 
precisely concerted signaling pathways of which the VEGF pathway is the one studied 
most extensively. 
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Figure 2. Vascular development. Endothelial cells and hematopoietic cells derive both from a 
common progenitor, the hemangioblast, which is characterized by VEGFR-2 (Flk-1) expression. 
Stimuli such as Notch signaling drive the angioblast differentiation (a). Notch signaling is involved 
in determining the arterial and venous fate of endothelial cells by promoting arterial cell fate (b). In 
the embryo the dorsal aorta and the cardinal vein derive directly from angioblasts promoted by 
vascular endothelial growth factor (VEGF), Sonic hedgehog (SHH), and Notch signaling. In the 
yolk sac, upon fusion of angioblasts a primitive capillary plexus arises. The Ephrin system is 
important for arterial-venous specification with Ephrin-B2 as an arterial marker and Eph-B4 
expressed on veins (c). Finally, stabilization and maturation of the new blood vessels is achieved 
by recruitment of mural cells, a process mediated by platelet-derived growth factor B (PDGF-B), 
transforming growth factor β(TGF-β), and angiopoietin-1 (ANG-1) signaling (d) (from [64]). 
 
Vascular endothelial growth factors (VEGF) and its receptors are the major players in 
embryonic and adult angiogenesis [59,65,66]. The mammalian VEGF family consists of 
five members, VEGF-A (also referred to as VEGF), VEGF-B, VEGF-C, VEGF-D, and 
placenta growth factor (PlGF). The VEGF ligands interact with three tyrosine kinase 
receptors, VEGF receptor (VEGFR)-1 (also Flt-1), VEGFR-2 (also known as KDR in 
humans or Flk-1 in mice), and VEGFR-3 (also Flt-4) [67,68]. VEGF-A binds to VEGFR-1 
and VEGFR-2 and mediates the majority of its biological effects through VEGFR-2 
signaling [65,66]. VEGF/VEGFR-2 signaling stimulates endothelial cell proliferation, 
migration, differentiation, sprouting, survival, and vascular permeability [63,66–68]. 
Vasculogenesis is controlled by a number of signaling molecules like fibroblast growth 
factors (FGF), the hedgehog family of morphogens, Neuropilins, transforming growth 
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factor-β (TGF-β) and its receptors, but the most pivotal role is dedicated to VEGF 
signaling with important roles in both, vasculogenesis and angiogenesis [63]. The 
indispensable role of VEGF/VEGFR-2 signaling at early developmental stages is 
reflected by the fact that VEGFR-2 marks hemangioblasts, a multipotent precursor, which 
can differentiate into cells of the hematopoietic lineage and into angioblasts [69]. 
Furthermore, numerous knockout studies underscored the crucial role of the 
VEGF/VEGFR system in the embryonic vascular development [66,68,70,71]. Mice 
lacking a single VEGF-A allele die at embryonic day 9.5, highlighting the significance of 
VEGF dosage for efficient embryonic vessel development [71,72]. 
 
3.2.2 Physiological angiogenesis 	
  
The formation of new blood vessels originating from preexisting vessels is a well-
characterized process implicated in the development of the cardiovascular system. 
Following the process of vasculogenesis, angiogenesis gives rise to a mature and 
complex vascular bed by remodeling of the primitive vascular labyrinth. This example of 
angiogenesis under physiological conditions is assigned to embryogenesis. Physiological 
angiogenesis in the adult is a rather infrequent event and occurs in the female 
reproductive cycle (ovulation, menstruation, implantation, pregnancy), during wound 
healing, and in the process of tissue regeneration [73–76]. 
Angiogenesis can take place by distinct mechanisms (Figure 3). Sprouting angiogenesis, 
which is the most widely studied mode of angiogenesis, refers to the formation of new 
blood vessels from a preexisting one (Figure 3a). The outgrowth of a novel vessel is 
initiated by numerous stimulatory angiogenic signals and requires proteolytic activities for 
the degradation of the endothelial basement membrane [77]. Growth factors activate 
endothelial cells to sprout, proliferate, mature, and remodel, finally resulting in expansion 
of the vascular network [78]. Vasculogenesis (Figure 3b) describes a mode of vessel 
formation by recruitment of endothelial progenitor cells followed by incorporation into 
vessel walls [79]. Intussusception is a specific form of angiogenesis where new vessels 
are formed by splitting of pre-existing vessels (Figure 3c). 
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Figure 3. Mechanisms of blood vessel formation. Angiogenesis can occur by sprouting 
angiogenesis (a), by recruitment of endothelial precursor cells (EPC) which undergo differentiation 
into endothelial cells (EC; b), or by splitting angiogenesis, a process known as intussusception (c). 
Modified from [79]. 
 
Intussusception is a mode of blood vessel formation that is not well understood. This new 
concept of blood vessel formation was first discovered during postnatal growth in the rat 
lung where it permits the increase of the capillary network [80]. In the third week of rat life 
and within the first two years in humans, the volume of the lung increases by more than 
20 times with expansion of the capillary volume of more than 30 times. Such an immense 
increment asks for a fast growth of the vasculature. Studying electron micrographs of rat 
lung vascular casts revealed that intussusceptive angiogenesis represents such a rapid 
process because it does not require proliferation of endothelial cells. Instead, remodeling 
of endothelial cells increases their volume in preparation for the following steps: 
transluminal contact formation, interstitial pillar generation, pillar growth in diameter, and 
endothelial cell retraction which eventually leads to separated vessels (Figure 4). In 
simplified terms, the capillary network extends within itself [81]. 
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Figure 4. Intussusceptive angiogenesis. Schematic illustration of the sequential steps involved 
in intussusceptive vascular growth. The process is initiated with the protrusion of opposite vessel 
walls towards the inside of the vessel lumen (a, a’, b, b’). When the endothelial cells have 
established an intercellular contact (c, c’), the endothelial layer and the basal membrane become 
perforated and a pillar is formed in the center of the vessel lumen (d, d’). Invading pericytes (Pr) 
and fibroblasts (Fb) produce collagen fibrils to stabilize the pillars (c’, d’) (from [81]).  
 
Endometrial growth in the menstrual cycle as well as vessel formation in the placenta 
after pregnancy depends on tightly regulated angiogenic processes, both involving 
growth and remodeling of the vasculature [73]. Injury of the dermis initiates 
neovascularaization as part of a successful wound healing process. The initial phase in 
wound healing is hemostasis resulting in fibrin-rich clot formation. Activated platelets and 
the fibrin-matrix, which forms the clot, provide a variety of angiogenic factors, including 
VEGF-A, that stimulate the sprouting of new vessels into the wound [82,83]. 
Liver regeneration represents another case of angiogenesis in the physiological setting 
that offers a reproducible model to study hepatic angiogenesis. After loss of hepatic 
tissue, the liver starts to regenerate and grows back to its normal mass [84,85]. Most of 
the current knowledge on the mechanisms regulating this highly complex and 
orchestrated phenomenon is gained from studies in the two-third partial hepatectomy 
(PHx) model performed in rodents. Higgins and Anderson introduced this experimental 
setup [86]. In a surgical procedure three of the five liver lobes are removed intact without 
damage of the residual lobes. In mice and rats, tissue regeneration is completed after five 
to seven days and the remaining liver enlarged to restore the original organ mass [84]. In 
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contrast to hepatic toxin (e.g. carbon tetrachloride) induced liver regeneration, PHx 
provides a regenerative impulse without inducing a response to inflammation or tissue 
damage. Liver regeneration after PHx involves sequential changes in gene expression, 
growth factor production, and morphologic structure. It is carried out by participation of all 
the existing mature liver cell populations, which are normally quiescent [84]. Hepatic 
angiogenesis is required to support the rapid increase in liver tissue and possibly 
terminates the regenerative process [87]. 
Given that there is no tissue damage after PHx to trigger the healing scenario, there must 
be another stimulus to induce the changes of signaling pathways in the liver. Even though 
the role of hemodynamic events after PHx are not well understood, it seems that the 
tremendous changes in the hepatic blood flow pattern induce hepatocyte proliferation 
through activation of hepatocyte growth factor (HGF) [88]. Hepatocytes are the first cells 
starting to proliferate, growing to avascular clusters. Cells located within the cluster are 
outside the oxygen diffusion distance of 100 - 200 µm [87,89]. Thus, they are exposed to 
hypoxic conditions which activate the transcription factor hypoxia inducible factor-1 (HIF-
1) followed by upregulation of downstream targets such as VEGF and VEGFR-1 [90]. 
VEGF secreted by proliferating hepatocytes peaks shortly after PHx [91,92]. VEGF 
promotes autocrine proliferation of hepatocytes besides stimulating the proliferative 
activity of sinusoidal endothelial cells in a paracrine fashion [91,93]. The enhanced 
expression of VEGF and its receptors coincides with the peak of endothelial proliferation 
[89,94]. VEGF does not only exert a proliferative stimulus to LSEC, but also permits 
migration of LSEC by breaking down the surrounding extracellular matrix through 
upregulation of collagenases, MMP, and urokinase-type plasminogen activator [95,96]. In 
addition, regulation of endothelial cell proliferation during hepatic regeneration involves 
other angiogenic factors including platelet-derived growth factor receptor beta (PDGF-R 
beta), epidermal growth factor receptor (EGF-R), and the angiopoietin/Tie system [89,94]. 
Angiopoietin-1 (Ang-1) mediates vessel stability through interaction with Tie-2, whereas 
Ang-2 antagonizes this effect [89]. Despite the close homology of Tie-1 with Tie-2, the 
former does not bind to angiopoietins and it’s exact role in angiogenesis remains to be 
elucidated [97]. Angiopoietin/Tie factors peak at 96 h after PHx, except for Ang-2, which 
shows the highest expression after 168 h. Ang-1 is likely to induce maturation of 
sinusoids presumably by interaction between endothelial cells and pericytes mediated 
through Tie-2 expressed on endothelial cells. Ang-2 in the absence of VEGF inhibits 
angiogenesis and might be associated with the cessation of the regenerative process 
[92]. These findings indicate a central role of angiogenesis in the course and termination 
of liver regeneration. 
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3.2.3 Pathological angiogenesis 	
  
Angiogenesis underlies a tightly controlled system consisting of pro-angiogenic and anti-
angiogenic factors. Disequilibrium in the angiogenic balance in favor of pro-angiogenic 
molecules turns on the “angiogenic switch” and contributes to the pathogenesis of many 
disorders such as cancer, psoriasis, rheumatoid arthritis, and diabetic retinopathy 
[74,76,98]. Pathologic angiogenesis recapitulates plenty of processes seen in 
physiological angiogenesis. Under both conditions, the same regulators are operating in a 
highly coordinated fashion. The difference between those two situations is that in 
pathological angiogenesis blood vessels grow uncontrolled without a termination phase 
once the vascular perfusion is established. Pathologic conditions drive the angiogenic 
cascade in a continuous manner eventually leading to development of “angiogenic 
diseases” [64]. Deregulated vessel growth in terms of insufficient vascular growth also 
impacts health, as it is associated with several diseases including heart ischemia, 
hypertension, neurodegeneration, osteoporosis, and many more [76,99]. 
In the pathologic situation of cancer, tumor angiogenesis is switched on. Tumor growth 
heavily depends on angiogenesis. As soon as the tumor reaches a size of 1-2 mm, 
formation of new blood vessels is necessary to supply tumor tissue with oxygen and 
nutrients by which further tumor growth is allowed. Because of the rapid tumor expansion 
and the irregular pattern of the tumor vasculature some cells become exposed to a 
hypoxic environment. Blood vessel recruitment in tumors is powered by tumor released 
factors and tumor hypoxia [100]. However, the tumor vessels are disorganized and leaky, 
reflecting their pathological nature. Although tumor vessel growth uses physiological 
mechanisms of angiogenesis it is obvious that in pathological stages coordination and 
restriction of the sequential events is impaired [101,102]. 
In the liver, pathological angiogenesis has been described during inflammatory and 
fibrotic processes in several chronic liver diseases of viral and autoimmune origin and in 
hepatocellular carcinoma [103–105]. In addition, excessive angiogenesis has been linked 
to the development of portal hypertension [106]. 
Portal hypertension is known to be associated with vascular changes occurring during 
chronic liver diseases. These vascular changes are not restricted to the liver, but are also 
present in the splanchnic and systemic circulation. Accordingly, there is an intrahepatic 
(increased vascular resistance) and an extrahepatic (increased hyperdynamic splanchnic 
circulation) contribution to the development of portal hypertension (Figure 5). It has long 
been known that cirrhosis is a vascular disease. In this context it appeared obvious that 
portal hypertension, which is most commonly caused by cirrhosis, is related to vascular 
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abnormalities. Indeed, numerous investigators substantiated this assumption by 
demonstrating that portal hypertension is a consequence of architectural changes of the 
hepatic circulation [39,107,108]. More recent findings also identified neovascularization 
implicated in the genesis of portal hypertension [103]. 
Intrahepatic vascular alterations: 
LSEC regulate the hepatic vascular tone by releasing vasoactive substances. However, 
in liver cirrhosis and portal hypertension the vasomotor property is deranged; 
production/bioavailability of vasodilators (i.e. nitric oxide) is decreased, whereas 
vasoconstrictors (i.e. thromboxane A2) are increased [42]. With this imbalance of 
vasodilators and vasoconstrictors, endothelial dysfunction contributes to an increased 
intrahepatic resistance. 
LSEC constitute the first line of defense, thus they are exposed to diverse types of liver 
injury. Inflammation, oxidative stress, insulin resistance, and alcohol are thought to be the 
main triggers of liver injury causing sinusoidal dysfunction [109]. In the liver, LSEC play 
important roles in the regulation of vasomotor control [109], blood clearance, immunity 
[110], hepatocyte growth [111], angiogenesis, and sinusoidal remodeling [112]. 
Therefore, LSEC dysfunction leads to impairment of these physiological effects. In liver 
cirrhosis, the sinusoidal circulation is characterized by “endothelial dysfunction” which 
results in a diminished bioavailability of endothelial relaxing factors, such as NO. This in 
turn causes an increase in the intrahepatic vascular resistance [113–115]. LSEC 
dysfunction can be seen as the primary event in the development of portal hypertension, 
as it initiates a cascade of structural and functional changes further contributing to the 
progression of portal hypertension. One consequence of LSEC dysfunction is the 
disruption of the crosstalk between LSEC and HSC, which is responsible for maintaining 
the sinusoidal homeostasis [39,116]. NO produced by LSEC preserves the quiescent 
state of HSC [107]. Because hypoactive endothelial cells in the cirrhotic liver generate 
reduced levels of NO, HSC become activated to a myofibroblastic phenotype [107]. 
Indeed, activated HSC contribute to accumulation of extracellular matrix and promote 
hepatic fibrosis following acute or chronic liver injury [33,37]. Fibrosis as well as active 
contraction of HSC gives rise to increased hepatic resistance based on a mechanic 
process [117]. At the same time the enhanced contractility and the presence of collagen 
induce capillarization of the sinusoids [39,107,118]. Furthermore, decreased NO 
production in LSEC disrupts the autocrine regulation of the LESC phenotype with 
dedifferentiation and capillarization [39]. As a consequence of defenestration and 
presence of a basement membrane during capillarization, the metabolic exchange with 
hepatocytes is physically impeded, sinusoids become more rigid, and hence 
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capillarization further enhances mechanically the sinusoidal vascular tone [42]. 
Altogether, LSEC dysfunction is a key factor in the pathophysiology of portal 
hypertension. 
Extrahepatic vascular alterations: 
Portal pressure is an important factor that triggers endothelial dysfunction in the intestinal 
microcirculation leading to the hyperdynamic state, characterized by splanchnic and 
peripheral vasodilatation, increased plasma volume, and increased cardiac output [119]. 
Dysfunctional endothelial cells, showing NO hyperproduction, are seen in cirrhosis and 
portal hypertension [42,120–122]. NO produced by eNOS is a vasodilatory agent 
considered as the major player in regulating arterial vasodilatation in the splanchnic and 
systemic circulation [120,123,124]. Besides NO, other vasodilator molecules are also 
found to be elevated in hyperactive endothelial cells, contributing to the arterial 
vasodilatation in the intestinal and splanchnic system [125–127]. The net effect of 
endothelial cell hyperactivation in the splanchnic and systemic circulation is vasodilatation 
in these vascular beds. In response to peripheral arterial vasodilatation, owing to 
increased vasodilators and decreased vasoconstrictors, a state of hypovolemia is 
simulated with ensuing activation of vasoconstrictive and volume-retaining neurohumoral 
mechanisms as well as increased cardiac output [128,129]. Compensatory sodium and 
water retention aims to perpetuate perfusion pressure by increasing the intravascular 
volume [130]. The hyperdynamic splanchnic circulation is mediated by arterial 
vasodilatation and expansion of blood volume [131]. As a result the blood flow in the 
splanchnic organs is increased with subsequent increase in portal venous inflow. In turn, 
increased flow to the portal vein aggravates portal hypertension [132,133]. 
To counterbalance the high pressure in the portal circulation, collateral vessels are 
formed. Collateral formation related to portal hypertension was traditionally thought to 
result from the opening of preexisting vessels [42,134]. However, recent studies 
demonstrated a role of angiogenesis in splanchnic hyperemia and collateral formation 
[135,136]. Portal pressure is sensed at the intestinal microciruculation, probably 
communicated by mechanical forces, switching on pro-angiogenic pathways [119]. 
Indeed, portal pressure has been shown to induce release of VEGF and PlGF providing 
evidence that angiogenesis plays a role in portal hypertension [137–139]. Such 
angiogenic growth factors facilitate splanchnic neoangiogenesis. Two effects result from 
these newly formed vessels. On the one hand, angiogenesis increases the splanchnic 
vascular bed size and therefore promotes increased blood supply in splanchnic organs. 
As they eventually drain into the portal vein, collaterals exacerbate portal hypertension 
[42,137]. On the other hand, formation of new blood vessels contributes to portal-
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systemic collaterals, including esophageal and gastric varices, which are responsible for 
variceal bleeding, related with high mortality [140]. In addition, collaterals are also 
involved in portal-systemic shunting, thereby causing severe complications such as 
portal–systemic encephalopathy [140]. 
Overall, angiogenic processes constitute a pathological hallmark of portal hypertension 
and inhibition of angiogenesis may be a novel approach to prevent disease progression 
and development of portal hypertension-associated complications [136,141]. 
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Figure 5. Pathophysiology of portal hypertension. Overview of the factors 
implicated in development of portal hypertension. LSEC dysfunction and endothelial 
dysfunction in the splanchnic and systemic circulation play a central role in 
development of portal hypertension and disease progression. 
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3.3 Notch signaling 
3.3.1 The Notch signaling pathway 	
  
Notch signaling is a highly conserved pathway involved in developmental and 
physiological cellular processes including cell fate decisions, differentiation, boundary 
formation, cell proliferation, and cell apoptosis [142,143]. Notch receptors and Notch 
ligands are both single-pass type I transmembrane proteins mediating intercellular 
communication to control pattern formation [144]. In mammals there are four Notch 
receptors (Notch1-4) and five Notch ligands belonging to the Delta and Jagged 
evolutionary conserved classes: Delta-like 1 (Dll1), Dll3, Dll4, Jagged1, and Jagged2 
[144,145]. The Notch receptor undergoes three proteolytical cleavages, named site 1 
(S1), site 2 (S2), and site 3 (S3). The first cleavage is essential for receptor maturation 
and occurs in the Golgi complex by a furin convertase, allowing the receptor to present as 
a heterodimer at the cell surface [143,145]. The latter Notch cleavages at S2 and S3 
depend on receptor-ligand interaction (Figure 6) [145]. 
Ligand binding to the Notch receptor activates Notch signaling by inducing two 
proteolytical cleavages. Upon ligand-receptor interaction a conformational change in the 
juxtamembrane receptor region is induced leading to S2 cleavage by ADAM 
metalloproteases ADAM10 (also known as Kuzbanian) and ADAM17 (also known as 
tumor necrosis factor α converting enzyme). The second cleavage triggers the following 
cleavage at the site S3 within the Notch transmembrane domain and is mediated by the 
multi-protein complex γ-secretase. The final cleavage releases the Notch intracellular 
domain (NICD), which can then translocate to the nucleus where it interacts with the 
DNA-binding protein CSL [144–146]. The CSL (named CBF1/RBPjκ in mammals) 
transcription factor is a negative regulator of Notch target genes. In the absence of NICD, 
CSL associates with transcriptional co-repressors. Binding of NICD to CSL displaces co-
repressors and recruits co-activators, in particular mammalian Mastermind-like 1 
(MAML1). The trimeric complex recruits histone acetylases and chromatin remodeling 
factors, which promotes transcription activation of target genes such as genes of the 
Hairy and Enhancer-of-split locus in Drosophila and the related Hes and Hey genes (i.e. 
Hes1 or Hey1) in mammals [144,146,147]. Given that Notch signaling is activated upon 
cell-to-cell contact, the pathway is important for directing cell fate specification, 
morphogenesis and organogenesis during development [143,145]. Consequently, 
dysregulation of Notch signaling has been implicated in a multitude of developmental 
defects, but is also involved in several human diseases, including many tumors [148,149]. 
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Figure 6. The Notch signaling pathway. The Notch receptor is cleaved by a Furin-like 
convertase at site S1 within the secretory pathway. This cleavage event converts the Notch 
receptor into a heterodimer consisting of the Notch extracellular domain (NEC) and the Notch 
transmembrane and intracellular domain (NTM).  The Notch receptor is activated upon binding 
to a ligand presented by a neighboring cell. This interaction induces a conformational change 
by which the site S2 is exposed for cleavage by ADAM metalloproteases. The generated 
membrane-anchored truncated NTM becomes a substrate for the γ-secretase complex. The γ-
secretase cleaves the intermediate NTM at site S3, which releases NICD. NICD then enters 
the nucleus, where it binds to the transcription fator CSL. NICD-CSL interaction facilitates 
displacement of transcriptional repressors (HDAC, SHARP, CIR and SMRT) and recruits 
coactivators  such as MAML and CBP/p300. The active transcription complex switches on 
transcription followed by upregulation of target genes. NHD, Notch heterodimerization domain; 
HDAC, histone-deacetylase; CIR, CBF1-interacting corepressor; SMRT, silencing mediator of 
retinoid and thyroid receptors; SHARP, SMRT/HDAC-1-associated repressor protein; CBP, 
CREB binding protein; CSL, CBF1/RBPj in mammals, Suppressor of Hairless in Drosophila, 
LAG in C. elegans (from [150]). 
 
3.3.2 Notch signaling in vascular development 	
  
The Notch signaling pathway plays a crucial role during vascular development, evidenced 
by the expression of Notch receptors and ligands in endothelial cells [151,152]. Gene 
inactivation strategies in mice have demonstrated that Notch signaling is crucial for the 
vascular-plexus remodeling of the primitive blood vessels. Global knockout of Notch1 and 
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Jagged1, Notch1/Notch4 double mutation, and Dll4 haploinsufficiency are embryonic 
lethal due to vascular defects [153–155]. The phenotype of these lethal Notch pathway 
mutants is characterized by the absence of angiogenic vascular remodeling of the 
primitive plexus. Notably, specific deletion of Notch1 in the endothelium recapitulates the 
vascular phenotype of Notch1 null embryos indicating that the observed growth arrest 
results from Notch1 loss in vessels [156]. Although Notch4 homozygous mutant mice are 
viable and show no obvious phenotype, Notch1/Notch4 double null embryos often display 
a more severe vascular phenotype than Notch1 homozygous mutant embryos [152]. 
Interestingly, generation of a transgenic mouse expressing activated Notch4 specifically 
in the endothelium exhibited a similar phenotype to that seen in Notch1 deficient mice 
with embryonic death [153,155]. The observation of angiogenic defects not only in 
knockout (loss-of-function) mice but also in transgenic (gain-of-function) mice suggests 
that embryonic vascular remodeling and morphogenesis depends on precisely regulated 
levels of Notch activity. Taken together, the severe phenotypes as a consequence of 
genetic ablation targeting Notch pathway molecules reveals the importance of Notch 
signaling during vessel pattern and network remodeling. 
Further, Notch signaling has been shown to regulate a number of events: artery-vein 
differentiation in endothelial and vascular smooth muscle cells, sprouting and branching 
of blood vessels during both normal development and tumor angiogenesis, as well as 
vascular smooth muscle cell differentiation [154]. 
The role of Notch signaling in cell-fate determination has been well established in multiple 
cell-types over the last years. Considering the artery-specific expression of several Notch 
receptors and ligands, it is obvious that Notch signaling is involved in the regulation of 
arteriovenous cell differentiation [157–159]. For many decades it had been believed that 
hemodynamic parameters trigger differentiation of arteries and veins before the concept 
of a genetically predetermined expression pattern was established. Whether an 
endothelial cell acquires an artery or vein identity, is defined by a genetic program 
already before the onset of blood flow. Notch signaling plays an important role during this 
arteriovenous differentiation as confirmed by genetic ablation studies [154,155,160]. 
Lawson et al. showed in zebrafish that disruption of Notch signaling leads to 
arteriovenous malformations. Notch mutant embryos displayed loss of artery-specific 
markers such as ephrin B2, at the same time venous markers like EphB4 and VEGFR3 
were ectopically expressed in the dorsal aorta [160]. The ectopic expression of activated 
Notch results in repression of a venous phenotype with a decrease of venous marker. 
However, Notch signaling activation was not able to induce arterial differentiation 
ectopically [160]. These findings suggest that the Notch signaling pathway regulates 
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arteriovenous differentiation by repressing the venous phenotype rather than inducing 
arterial differentiation during embryonic vascular development [160]. Further 
investigations revealed that arterial specification of endothelial cells in zebrafish embryos 
arises from a complex signaling cascade linking the Notch pathway to VEGF signaling. 
VEGF, whose expression is induced by sonic hedgehog (Shh) acts upstream of Notch 
signaling, which mediates arterial differentiation by enhancing the expression of the 
artery-specific marker ephrinB2, which is a direct target of the Notch pathway [161,162]. 
Angiogenesis is the process of new blood vessel formation from an existing vascular 
network. VEGF is known to induce angiogenic sprouting by activating quiescent 
endothelial cells, which subsequently adopt different phenotypes depending on their role 
in the growing sprout [163]. The cell in the front of the sprout is the tip cell. Its very motile 
but non-proliferative features allow the tip cell to explore the environment for growth 
factor signals and to lead the outgrowth of vessel sprouts. The cells following behind the 
tip cell become stalk cells, which are highly proliferative cells that form the vascular lumen 
[163]. To guarantee an organized vascular extension of the primary capillary plexi a 
mechanism is required that limits the number of outgrowing vessel sprouts and restricts 
the nomination of tip cells to a small subset of endothelial cells. Several studies in the 
mouse retina, zebrafish embryo, tumor xenograft models, and in vitro cell culture assays 
have shown that the Notch pathway regulates which cell turns into a tip cell and which 
cells differentiate into stalk cells in response to VEGF signaling (Figure 7) [164–168]. In 
endothelial tip cells Dll4 and VEGFR-2 are highly expressed compared to neighboring 
stalk cells, where Notch activity is prominent. Dll4 expressing endothelial cells activate 
Notch signaling and negatively regulate VEGFR-2 expression in adjacent cells. Thereby 
Dll4/Notch signaling suppresses the tip-cell fate and thus prevents sprouting of these 
cells. Disruption of Dll4/Notch signaling goes along with increased tip cell formation, 
sprouting and branching of the vasculature [164–167]. On the molecular level, tip cell 
markers like Pdgfb and Unc5b are upregulated at the vascular front in Dll4 mutant retinas 
[164,165]. In summary, Dll4/Notch signaling, stimulated by VEGF, restricts the tip cell 
phenotype to a confined number of cells, thereby preventing excessive vessel sprouting 
and promoting normal vascular morphogenesis. 
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Figure7. Tip-stalk cell differentiation. The tip cell 
becomes selected by sensing a higher levels of 
VEGF. VEGF/VEGFR signaling induces 
expression of Dll4 in tip cells. Dll4, in turn, 
activates Notch signaling in adjacent cells to 
reduce expression of VEGFR2 and VEGFR3. Dll4-
mediated Notch signaling is required for stalk cell 
specification by efficiently suppressing the tip-cell 
fate in these cells. Thereby, Notch signaling limits 
the number of tip-cells and vascular sprouts. 






3.3.3 Notch signaling in vascular disease 	
  
Most of the Notch pathway roles in blood vessels were studied in models for 
developmental angiogenesis. Embryonic lethality of null mutant mice for several 
members of the Notch pathway made analysis of the Notch signaling in the adult vascular 
physiology difficult. Thus, Notch functions in the postnatal vasculature are not well 
understood. The identification of mutations in Notch pathway components associated with 
human vascular diseases improved our understanding of Notch signaling in vascular 
homeostasis. Notch signaling impairment has been found to be involved in two hereditary 
vascular pathologies: the Alagille syndrome (AGS) and the cerebral autosomal dominant 
arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL). 
The inherited degenerative vascular disease CADASIL is due to Notch3 mutations [170]. 
This adult-onset disease manifests with stroke and dementia [171,172]. The pathology 
underlying the condition is a progressive degeneration of the vascular smooth muscle 
cells (SMC) and the accumulation of granular osmophilic material (GOM) [170]. The 
specific Notch3 expression pattern, highly restricted to the smooth muscle layer, 
implicates abnormalities in vascular smooth muscle cells eventually leading to their 
degeneration [153]. CADASIL is considered to be a systemic vascular disorder since 
destruction of the smooth muscle layer and GOMs has also been found in muscle and 
skin biopsies [173]. However, vascular perturbations are restricted to the brain [174]. The 
late-onset of CADASIL underlines the importance of Notch signaling in adult stages by 
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regulating vascular homeostasis and maintaining differentiation of the mature blood 
vessels. 
 
AGS is caused by a mutation in the Jagged1 gene. In a small group of AGS patients, 
mutations in the Notch2 receptor were identified [175]. The clinical presentation of this 
autosomal dominant disorder is defined by developmental abnormalities of the liver, 
heart, eye, and skeleton [176,177]. Initially, AGS has been described as a syndrome 
characterized by bile duct paucity in conjunction with cardiac defects, skeletal 
abnormalities, ocular abnormalities, and characteristic facial features. Vascular 
abnormalities, already appreciated in the alternative name “arteriohepatic dysplasia”, 
have been described in multiple AGS patients supporting the idea of a vascular 
involvement in this disorder as well as the significant role of Notch signaling in vascular 
homeostasis [178]. 
Very little is known about the role of Notch signaling in the adult liver vasculature and the 
molecular mechanisms regulating hepatic vascular maintenance are not well understood. 
RBP-J is the key mediator of Notch signaling for all four Notch receptors. Deletion of 
RBP-J in mice leads to defects in LSEC with SOS-like disease and impaired liver 
regeneration, suggesting a fundamental role of Notch signaling in the liver vasculature. 
[32] In mice, rats, and monkeys chronic Dll4 blockade induces histopathological changes 
of the liver, affecting endothelial cells as well as hepatocytes [179]. Furthermore, Notch1 
heterozygosity induces vascular tumors in mice, predominantly occurring in the liver 
reflecting that Notch1 expression is essential in the normal liver [180]. 
Although Notch signaling has been shown to play a role in the human adult liver in 
physiological and disease state, further studies are needed to elucidate how the Notch 
pathway coordinates homeostasis of the adult hepatic vasculature [181].
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3.4 Aim of the thesis 
 
The Notch1 signaling pathway is crucial for angiogenic vascular remodeling during 
embryogenesis, but its role in postnatal angiogenesis remains elusive. Since the 
knowledge on the function of Notch1 signaling in the liver vasculature is very limited 
together with the fact that our laboratory has a conditional Notch1 KO mouse model 
available, which shows a liver phenotype, we made it to our goal to characterize the role 
of the Notch1 pathway in the adult hepatic microcirculation and in pathologic conditions. 
 
Global loss of Notch1 results in embryonic lethality due to vascular defects [152]. 
Generation of endothelial-specific deletion of Notch1 was found to recapitulate the 
vascular defects observed after global Notch1 KO and proves an endothelial defect to be 
responsible for the angiogenic failure during embryogenesis rather than failure of extrinsic 
signals from nonvascular tissue [156]. However, the role of Notch1 signaling in adult 
angiogenesis remains to be clarified. Therefore, we wanted to assess the role of Notch1 
in the liver vasculature and LSEC with specific regard to vascular homeostasis, 
differentiation, and quiescence.  
 
In our laboratory it has been previously shown, that deletion of Notch1 induces nodular 
regenerative hyperplasia in mice [182]. This finding has made the MxCre Notch1 KO 
mouse an excellent experimental model to study the pathomechanisms of a liver 
pathology that is also present in humans. Although it has long been established that 
human NRH results from hemodynamic disturbances, the exact pathogenesis is still not 
known. Furthermore, data on molecular mechanisms of the disease are not available. 
Thus, the aim of our animal study was to dissect the mechanisms involved in the 
development of NRH and to assess how Notch1 deficiency is associated to the 
development of this liver condition. In support of the hypothesis that NRH is linked to a 
vascular injury we wanted to identify angiogenic processes contributing to the 
pathological changes and to study endothelial markers associated with this disease.  
 
NRH is a rare liver condition that in some patients can lead to development of portal 
hypertension. NRH has been shown to be associated with autoimmune, hematological, 
infectious, neoplastic, or drug-related causes. Unlike the large post-mortem autopsy 
study by Wanless, all reported conditions associated with NRH are based on single case 
reports or case series and systemic population studies on NRH are missing. In a 
translational study using patient liver biopsies we aimed to establish a correlation 
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between NRH severity and the presence of portal hypertension. In analogy to our mouse 
model, we analyzed if the same set of genes are also regulated in patients with NRH 
favoring a vascular injury at the sinusoidal level as the underlying cause of this disease. 
Thus, our study provides first insights into the molecular pathogenesis of NRH. 
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4. Results 
4.1 Disruption of Notch1 induces vascular remodeling, 
intussusceptive angiogenesis, and angiosarcomas in livers of 
mice 
 
Michael T. Dill *, Sonja Rothweiler *, Valentin Djonov, Ruslan Hlushchuk, Luigi Tornillo, 
Luigi Terracciano, Silvia Meili-Butz, Freddy Radtke, Markus H. Heim and David Semela. 
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ERBACKGROUND & AIMS:Notch signaling mediates em-
ryonic vascular development and normal vascular re-
odeling; Notch1 knockout mice develop nodular regen-
rative hyperplasia (NRH). The pathogenesis of NRH is
nclear, but has been associated with vascular injury in
he liver sinusoids in clinical studies. We investigated the
ole of Notch1 signaling in liver sinusoidal endothelial
ells (LSECs). METHODS: We studied MxCre Notch1lox/lox
mice (conditional knockout mice without tissue-specific
disruption of Notch1); mice with hepatocyte-specific
knockout were created by crossing Notch1lox/lox with Alb-
Cre/ mice. Portal vein pressure was measured; morphol-
ogy of the hepatic vasculature was assessed by histologic
and scanning electron microscopy analyses. We performed
functional and expression analyses of isolated liver cells.
RESULTS: MxCre-induced knockout of Notch1 led to
NRH, in the absence of fibrosis, with a persistent increase
in proliferation of LSECs. Notch1 deletion led to de-differ-
entiation, vascular remodeling of the hepatic sinusoidal
microvasculature, intussusceptive angiogenesis, and dys-
regulation of ephrinB2/EphB4 and endothelial tyrosine
kinase. Time-course experiments revealed that vascular
changes preceded node transformation. MxCre Notch1lox/lox
mice had reduced endothelial fenestrae and developed
portal hypertension and hepatic angiosarcoma over time.
In contrast, mice with hepatocyte-specific disruption of
Notch1 had a normal phenotype. CONCLUSIONS:
Notch1 signaling is required for vascular homeostasis
of hepatic sinusoids; it maintains quiescence and dif-
ferentiation of LSECs in adult mice. Disruption of
Notch1 signaling in LSECs leads to spontaneous for-
mation of angiosarcoma, indicating its role as a tumor
suppressor in the liver endothelium.
Keywords: Vascular Tumor; Liver Cancer; Ephrin Signal-
ing; Sinusoidal Capillarization.
The hepatic sinusoidal microvasculature is composedof a highly specialized and differentiated endothe-
ium characterized by a discontinuous, fenestrated endo-
helial lining without a basement membrane.1 The liver
inusoidal endothelial cells (LSECs) comprise half of the
onparenchymal cells of the liver and play a central role in
any physiological functions, including liver organogen-
sis, liver regeneration, control of the vasomotor tone,cavenger functions, blood cell trafficking, prevention of
epatic stellate cell (HSC) activation, and production of
aracrine factors such as hepatocyte growth factor and
nterleukin-6.1–5 Chronic liver disease can lead to endo-
helial dysfunction and dedifferentiation of LSECs with
oss of fenestrations, deposition of a basement membrane,
nd surface expression of CD31, a process that has been
ermed sinusoidal capillarization and that precedes liver fi-
rosis.6,7 The determinants regulating the normal, differ-
ntiated LSEC phenotype are only incompletely under-
tood. Paracrine secretion of vascular endothelial growth
actor (VEGF) by hepatocytes and HSCs as well as auto-
rine production of nitric oxide by endothelial NO syn-
hase have been shown to be essential to maintain the
henotype of LSECs.6 However, other signaling pathways,
he absence of shear stress, and interendothelial and het-
rotopic contact with HSCs might be additional impor-
ant determinants of LSEC differentiation.
The Notch signaling pathway is an intercellular signaling
echanism that controls endothelial cell differentiation, ar-
eriovenous specification, and vascular development.8,9
Notch signaling mediates intercellular communication
through membrane-bound receptors (Notch1–4) and li-
gands (Jagged-1, -2, and Delta-like-ligand [Dll]1, 3, and
4).8,10 The Notch signaling pathway involves ligand-in-
duced activation of the receptor, proteolytic cleavage, and
subsequent translocation of its intracellular domain
(NICD) to the nucleus, where it acts as a transcriptional
regulator. Notch1 is expressed in normal liver and has
been detected in hepatocytes, biliary epithelial cells, and
LSECs.11 Jagged-1 and Notch2 mutations have been
hown to cause Alagille syndrome, a condition leading to
ile duct paucity and cardiovascular defects at birth.12,13
Notch1, 3, and 4 and their ligands Jagged-1, Jagged-2, and
Dll4 are expressed in blood vessels.14 Mutations in
Abbreviations used in this paper: BrdU, 5-bromo-2’-deoxyuridine;
DAPT, N-[(3,5-difluorophenyl)acetyl]-L-alanyl-2-phenyl]glycine-1,1-di-
methylethyl ester; Dll4, Delta-like-ligand-4; ECM, endothelial cell me-
dium; HSC, hepatic stellate cell; KO, knockout; LSEC, liver sinusoidal
endothelial cell; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide; NRH, nodular regenerative hyperplasia; pIpC, polyiosinic-
polycytidylic acid; SEM, scanning electron microscopy; VEGF, vascular
endothelial growth factor; WT, wild-type.





































968 DILL ET AL GASTROENTEROLOGY Vol. 142, No. 4Notch3 cause inherited vascular diseases, such as the
degenerative vascular disorder cerebral autosomal-domi-
nant arteriopathy with subcortical infarcts and leukoen-
cephalopathy.8 However, the function of Notch1 in the
iver is unknown.
We previously reported that knockout of the receptor
otch1 in mice leads to development of nodular regen-
rative hyperplasia (NRH) in the liver.15 NRH is a specific
histopathologic entity in human beings that can be com-
plicated by portal hypertension; however, the etiology and
pathogenesis of NRH remain unclear. Several reports have
linked NRH to vascular injury of the sinusoidal microcir-
culation (ie, by toxins, drugs, arteritis, or thromboembolic
events).16–19 The observation that the final common path-
way of NRH might be an endotheliopathy and that
Notch1 signaling is crucial for vascular differentiation led
us to explore the role of Notch1 as a regulator of LSEC
phenotype in the sinusoidal microcirculation.
In the present study, we show that Notch1 signaling is
required for vascular homeostasis of hepatic sinusoids by
inducing quiescence and differentiation of LSECs in adult
mice. Disruption of the Notch1 pathway leads to LSEC
proliferation, vascular remodeling, capillarization with
loss of fenestrae, and to the development of portal hyper-
tension and, eventually, angiosarcoma.
Materials and Methods
Animals, Induction of Notch1 Deletion,
Genotyping, and Southern Blotting
MxCre Notch1lox/lox mice on a C57Bl/6 background
carry the Cre-recombinase under the murine Mx1 promoter. To
induce recombination, 300 g of polyiosinic-polycytidylic acid
(pIpC) (InvivoGen, San Diego, CA) was injected intraperitoneally
in 4-week-old mice at days 0, 3, and 6, resulting in efficient
deletion of Notch1 in the liver already after 1 day.
Hepatocyte-specific Notch1 knockout (KO) mice were gener-
ated by crossing MxCre- Notch1lox/lox mice with AlbCre/ mice
n a C57Bl/6 background (Jackson Laboratory, Bar Harbor,
E), expressing Cre-recombinase under the hepatocyte-specific
lbumin promoter. Single transgenic Notch1lox/lox or Cre lit-
termates of each strain were used as controls. Newborn mice
were genotyped as previously described.20 The efficiency of
Notch1 deletion was checked regularly by DNA extraction from
livers and subsequent Southern blot analysis with a Notch1-
specific probe as previously described.20 Notch1 deletion was
onsistent in LSECs and hepatocytes during the whole observa-
ion period.
Animals were maintained in the animal facility of the Depart-
ent of Biomedicine at the University Hospital Basel, in a
pecific-pathogen-free environment on a 12-hour light and 12-
our dark schedule. Food and drinking water were provided ad
ibitum. All experiments were approved by the veterinary office
f Basel.
Macroscopic and Microscopic Assessment of
Livers After Notch1 Deletion
Mice were harvested at different time points after recom-
bination as indicated in the text. After measuring the body
weight, the livers were removed, assessed macroscopically, and
weighed. From all livers, parts were immediately shock frozenfor further analysis, the rest was fixed in 4% formaldehyde and
processed for standard histologic assessment with H&E staining.
For 5-bromo-2’-deoxyuridine (BrdU) labeling of cells in the S
phase of the cell cycle, mice were given 0.8 mg/mL of BrdU
(Sigma, Buchs, Switzerland) by drinking water for 1 week. BrdU
incorporation was detected by immunohistochemistry with an
anti-BrdU antibody (Roche Diagnostics, Rotkreuz, Switzerland)
and avidin biotin complex (ABC-Eite; Vectra Laboratories, Ge-
neva, Switzerland). The average amount of positive hepatocytes
and LSECs was assessed in 10 high-power fields by 2 indepen-
dent observers (M.T.D., D.S.) in a blinded fashion.
For immunohistochemistry, formalin-fixed and paraffin-em-
bedded 4-m–thick mouse liver sections were dewaxed, rehy-
rated, pretreated for 5 minutes in an autoclave with Tris/
DTA/citrate (TEC) buffer, pH 8, incubated with the respective
rimary antibody (Supplementary Table 1) and counterstained
ith hematoxylin. Standard indirect immunoperoxidase proce-
ures were used (ABC-Elite).
Measurement of Portal Vein Pressure
Wild-type (WT) and KO mice 2, 8, and 16 weeks after
pIpC injection and Notch1 deletion, were anesthetized with an
intraperitoneal injection of 2 g/g body weight of a narcotics
mix (medetomidine 1 mg/mL, climazolam 10 mg/mL, fentanyl
50 g/mL). A midline laparotomy was performed and the portal
vein was cannulated through the superior mesenteric vein with
a 30-gauge needle connected to a highly sensitive pressure trans-
ducer (MLT1050 Pressure Transducer; AD Instruments, Spech-
bach, Germany). The external zero reference point was placed at
the midportion of the animal. The measurements were recorded
on a multichannel computer-based recorder.
Fluorescein Isothiocyanate–Formaldehyde–
Treated Serum Albumin Monomer Application
Eight weeks after pIpC injection, WT and KO mice were
anesthetized as described. A midline laparotomy was performed
and 1.12 g/g body weight of fluorescein isothiocyanate–for-
aldehyde–treated serum albumin monomer (a gift from Dr
ard Smedsrød, University of Tromsø, Norway)21 was injected
into the portal vein. Thirty minutes later the mice were exsan-
guinated and the livers were harvested. Sections were obtained as
described earlier and analyzed by fluorescence microscopy.
Scanning Electron Microscopy
Methylmethacrylate corrosion casts were performed as
followed: the vasculature of the murine liver was perfused in situ
via the portal vein with a freshly prepared solution of Methyl-
methacrylate (Mercox, Vilene Company, Tokyo, Japan) contain-
ing 0.1 mL of accelerator per 5 mL of resin. One hour after
perfusion, the livers were excised and transferred to a 15% KOH
solution for the dissolution of the tissue, which was achieved
within 3–4 weeks. After washing, casts were dehydrated in eth-
anol and dried in a vacuum desiccator.
For normal scanning electron microscopy (SEM) analysis, the
liver was perfused with fixative (2.5% glutaraldehyde in 0.1
mol/L cacodylate buffer [pH 7.4, 350 mOsm]). Then the liver
was excised, cut into small pieces, and immersed in the same
fixative as used for perfusion. Samples then were processed as
the casts. All samples were mounted on aluminium stabs, sput-
ter-coated with gold, and viewed under a Philips XL 30 Super
FEG scanning electron microscope (Philips, Zurich, Switzer-
land). Sinusoidal diameters were evaluated by measuring the













































April 2012 NOTCH1 IN HEPATIC MICROCIRCULATION 969ware (Olympus Soft Imaging System, Muenster, Germany).
Branching was assessed by counting branching points and nor-
malizing to the total tube length of the capillary network in
calibrated TIFF files.
To evaluate fenestrae and sieve plates, planar endothelial
areas were photographed and saved as calibrated TIFF files;
fenestrae and sieve plates were quantified and morphometrically
analyzed in representative areas using CellP software.
Cell Culture
Isolated primary human LSECs (ScienCell, Carlsbad,
CA) were used between passages 2 and 6. Their phenotypic
characterization has been described previously.22 LSECs were
cultured in endothelial cell medium (ECM; ScienCell), and sup-
plemented with 10% fetal bovine serum (FBS), L-glutamine (1
mmol/L), penicillin (100 IU/mL), and streptomycin (100 g/
L). In experiments investigating supernatant from murine
epatocytes, transformed murine LSECs (a gift from Dr Vijay
hah, Mayo Clinic) were used as previously described.23
LSECs, HSCs, and Hepatocyte Isolation and
Conditioned Medium
LSECs,HSCs, andhepatocyteswere isolated fromNotch1KO
andWTmice and purified as previously described.24 Briefly, livers were
erfusion-digested with collagenase (Liberase TM Research Grade;
oche, Basel, Switzerland) followed by separation of hepatocytes and
onparenchymal cells by centrifugation. LSECs and HSCs were iso-
ated further by centrifuging over a Percoll gradient and purified by
elective adhesion. Purity of isolated cells was verified by fluorescein
sothiocyanate–FSA uptake in LSECs, by retinoid autofluorescence in
SCs, and by hepatocyte nuclear factor 4 alpha (Supplementary Table
) immunostaining in hepatocytes, confirming greater than 90% pu-
ity. Isolated cells were used immediately for RNA extraction. Isolated
epatocytes and HSCs also were cultured in plastic culture dishes
ontainingDulbecco’smodifiedEaglemediumovernight.Hepatocytes
ubsequently were incubated with serum-free ECM. After 24 hours
upernatant was harvested, filtered through a 0.2-m filter, and ali-
quots were stored at 20°C. HSCs were used further for co-culture
tube formation assay.
3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide (MTT) Assay
Cell viability and proliferation of murine LSEC was
assessed by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) assay. LSECs were seeded in 96-well plates
in complete ECM. After 4 hours cells were washed twice and
incubated overnight at 37°C with conditioned medium derived
from Notch1 KO or WT hepatocytes. FBS–free ECM was used as
a negative control. Cells then were incubated for 24 hours at
37°C with 333 g/mL MTT solution. Absorbance was measured
at 490 nm.
Vascular Tube Formation Assay
Cultured LSECs were seeded on Matrigel-coated, 4-well
chamber slides (Lab-Tek, Fisher Scientific, Wohlen, Switzerland)
with a total of 2  104 cells per well.22 The complete wells were
photographed after 16 hours of incubation at 37°C in FBS–free
ECM. Total vascular tube length per well was analyzed digitally
using the software CellP. In some experiments, LSECs were
incubated with the Notch inhibitor N-[(3,5-difluorophenyl)
acetyl]-L-alanyl-2-phenylglycine-1,1-dimethylethyl-ester at 1
mol/L (DAPT, Sigma) versus dimethyl sulfoxide or co-cultured with
isolated HSCs in a ratio of 3:1.RNA Extraction, Quantitative Reverse-
Transcription Polymerase Chain Reaction
Total RNA was extracted from isolated cells by col-
umn separation and DNase treatment (Nucleospin kit;
Machery-Nagel, Oensingen, Switzerland) according to the
manufacturer’s instructions. A total of 1 g of RNA was
everse-transcribed and real-time polymerase chain reaction
as performed using the SYBR green polymerase chain reac-
ion master mix (Applied Biosystems, Foster City, CA). In-
ron-spanning primers are listed in Supplementary Table 2.
ll reactions were run in duplicate using a 7500 Fast Real-
ime Polymerase Chain Reaction System (Applied Biosys-
ems). Messenger RNA (mRNA) expression levels of the tran-
cripts were normalized to RPL19 using the Ct method.
Statistical Analysis
Comparisons were performed by the Student t test (un-
less otherwise specified) using Graph Pad Prism 4.0 software (in
the figures *designates statistical significance when P  .05,
**P  .01, and ***P  .001, respectively).
Results
Deletion of Notch1 Leads to LSEC Activation
and Portal Hypertension
We previously reported that deletion of Notch1 in
MxCre Notch1lox/lox mice, further described as KO mice,
leads to increased liver weight, hepatocyte proliferation,
nodular transformation, and phenotypic changes iden-
tical to NRH described in patients15 (Figure 1A–C). To
explore the concept, that a cause of NRH might be a
dysfunctional endothelium in the liver, we examined
the sinusoidal compartment in these KO mice. KO mice
showed areas with widened sinusoidal spaces located in
the periphery of the nodules (Figure 1B). LSECs were
found to have increased proliferation rates 14 days after
pIpC injection, suggesting persistent activation (Figure
1C and E). Increased hepatocyte proliferation occurred
already after 6 days and was localized mainly in the
center of the nodules (Figure 1C and D). Because portal
hypertension is a known complication of NRH, we
assessed portal pressure in KO mice with fully devel-
oped NRH by cannulation of the portal vein 16 weeks
after pIpC injection. In comparison with controls, KO
mice developed a significant increase in portal pressure
(Figure 1F). Unexpectedly, portal pressure already was
increased significantly before the onset of NRH (ie, 2
weeks after pIpC injection; Figure 1F), suggesting the
presence of increased intrahepatic vascular resistance
before nodular transformation of the liver parenchyma.
Loss of Notch1 Signaling Induces Vascular
Remodeling Through Intussusceptive
Angiogenesis
Next, to explore the 3-dimensional morphology
of the hepatic microcirculation, we studied vascular
casts by SEM. Surprisingly, KO mice showed extensive
remodeling of the sinusoids with a plexus-like appear-
























970 DILL ET AL GASTROENTEROLOGY Vol. 142, No. 4(Figure 2A and B). Further, casts already revealed abun-
dant formation of pores 2 days after pIpC injection
(Figure 2A and B, arrowheads), which are the hallmark of
intussusceptive angiogenesis. This is in contrast to
sprouting angiogenesis, which is the primary mode of
blood vessel formation (by endothelial cell prolifera-
tion, migration, sprout formation with recanalization).
Intussusceptive angiogenesis on the other hand defines
the angiogenic process in which transluminal tissue
Figure 1. Notch1 knockout in MxCre mice leads to hepatocyte and L
evelopment of liver weight vs body weight ratio in MxCre Notch1lox/lox (K
pIpC injection (n 7 animals per time point, mean with standard deviatio
Black dotted lines outline regenerative nodules. At the periphery of nodule
was given by drinking water 7 days before the harvest. Liver sections w
rdU-positive hepatocytes localized in the regenerative nodules (arrows
eriphery of the nodules (arrowheads). Shown are representative pictur
epatocytes in 10 random high-power fields per animal was assessed a
oint, mean with standard error of the mean). (E) BrdU-positive LSEC
epatocytes, a delayed but significant increase in proliferation rate. (F
easured by canulation of the portal vein at the indicated time points afte
ith controls with standard deviation).pillars develop within capillaries, small arteries, andveins (Figure 2C), and subsequently fuse, thus delineat-
ing new vascular entities or resulting in vessel remod-
eling (Supplementary Figure 1). The process of angio-
genesis and vascular remodeling led to an increased
variation of the sinusoidal diameter (Figure 2D) and
increased branching within the microcirculation (Fig-
ure 2E). Accordingly, complementary experiments with
isolated human LSECs showed increased vascular tube
formation after pharmacologic Notch inhibition by the
C proliferation and development of increased portal vein pressure. (A)
nd MxCre- Notch1lox/lox (WT) mice over time after the first intraperitoneal
B) H&E-stained liver sections of KO mice 14 weeks after recombination.
ilated sinusoids can be identified (bar 250 m). (C) BrdU (0.8 mg/mL)
stained for nuclear BrdU incorporation (bar  100 m). KO mice had
hereas positive LSECs were found mainly in the dilated sinusoids at the
4 weeks after pIpC injection. (D) The average amount of BrdU-positive
showed increased hepatocyte proliferation rate (n  6 animals per time
ere quantified as described in panel D and showed, compared with
O mice developed increased portal vein pressure. The pressure was








































April 2012 NOTCH1 IN HEPATIC MICROCIRCULATION 971Notch1 Signaling Is Essential for LSEC
Differentiation
The hepatic microcirculation is a highly differen-
Figure 2. Loss of Notch1 signal-
ing leads to vascular remodeling
through intussusceptive angio-
genesis. (A) SEM analysis of vas-
cular casts in WT and KO mice 8
weeks after pIpC injection showed
architectural changes of the hepatic
microcirculation in KO mice (low
magnification at top, higher magni-
fication at bottom;bar50m). At
ighermagnification,casts revealed
ores (red arrowheads), the hall-
arkof intussusceptiveangiogene-
is. (B) Time-course SEM analy-
is in KO revealed pore formation
red arrowheads) 2 days after the
rst pIpC injection and partial re-
odeling of the sinusoids after 2
eeks (bar 20m). (C) Endovas-
cular pillars, the corresponding in-
traluminal structures to the pores of
intussusception, were found in KO
SEM samples but not in WT 2
weeks after pIpC injection (middle
picture with adjacent erythrocyte of
7.5m next to the pillar). (D) Sinu-
soidal diameters were analyzed in
mice8weeksafterpIpC injectionby
measuring the diameter of the sinu-
soids between 2 branching points
at the narrowest site. Deletion of
Notch1 led to a strong variation in
diameters with a significantly in-
creased average diameter (n  3
animals per group with 250 data
points assessed per group; P 
.0001, Mann–Whitney test). (E)
Branching points of the sinusoidal
vascular network were quantified in
mice 8 weeks after pIpC injection
(red diamonds) by dividing the total
tube length of the vessels by the
quantified branching points within
the network.Notch1 deletion led to
increased branching with shorter
vascular intersections. (F) Pharma-
cologic inhibition of Notch signaling
by DAPT (1 mol/L) led to in-
creased angiogenesis of primary
human LSECs in vitro. Total vascu-
lar tube formation of human LSECs
on Matrigel in 4-well chamber slides
was quantified digitally after 16
hours of incubation (3 independent
experiments in duplicates).tiated endothelium characterized by the presence of fenes-trae, sieve plates, and scavenger receptor activity. We
therefore analyzed whether these LSEC-specific features
are influenced through Notch1 signaling. The deletion of





























972 DILL ET AL GASTROENTEROLOGY Vol. 142, No. 4sieve plates within 2 weeks (Figure 3A and B). The remain-
ing fenestrae were characterized by a significant increase
in diameter (Figure 3B). This dedifferentiation was evi-
denced further by up-regulation of CD31, which is a
marker of capillarization in diseased LSECs in disorders
Figure 3. Notch1 signaling is essential for LSEC differentiation. (A and
B) SEM of hepatic sinusoids revealed a significant reduction of fenestrae
and sieve plates after loss of Notch1 by morphometric analysis (bar 2
m). The remaining fenestrae in KO mice had a significantly increased
iameter (n  4 animals per group, 2 weeks after pIpC injection). (C)
mmunohistochemistry for the endothelial surface marker CD31 showed
p-regulation in the membrane of LSECs of KO mice in comparison with
T (bar  100 m; 12 weeks after pIpC injection), indicating dediffer-
entiation and capillarization of the sinusoids. (D) LSEC-specific uptake of
fluorescein isothiocyanate–serum albumin was not influenced after de-
letion of Notch1, indicating normal scavenger function (bar  100 m;
2 weeks after pIpC injection).such as fibrosis and hepatocellular carcinoma and havebeen shown to be correlated inversely with LSEC fenes-
tration6 (Figure 3C). To assess another specific function of
LSECs, namely the clearance of certain macromolecules
by scavenger receptors,21 we studied the uptake of fluo-
escein isothiocyanate–albumin after portal vein injection
y fluorescence microscopy (Figure 3D). This specific
unction remained unchanged after Notch1 KO, highlight-
ing that LSECs after loss of Notch1 retain a certain degree
of differentiation and functionality.
To exclude the possibility that the observed changes of
the hepatic microvasculature in MxCre Notch1lox/lox mice
are only secondary to effects on hepatocytes, we generated
a hepatocyte-specific knockout by crossing Notch1lox/lox
with AlbCre-positive mice (AlbCre KO mice). The success-
ful recombination was confirmed by Southern blot (Fig-
ure 4A). These hepatocyte-specific Notch1 KO mice were
phenotypically normal (liver parenchyma without nodu-
larity microscopically and macroscopically, normal liver
weight, normal vascular morphology) and showed no in-
creased proliferation rates of hepatocytes or LSECs at the
same time points as in MxCre KO mice (Figure 4B and C,
and data not shown). Isolated LSECs incubated with con-
ditioned media from normal versus MxCre Notch1 KO
primary hepatocyte cultures showed no difference in the
MTT proliferation assay or in vitro capillary tube forma-
tion (Figure 4D). Expression of mitogens such as VEGF,
fibroblast growth factor, angiopoietins, and transforming
growth factor 1 also were unchanged in isolated hepa-
tocytes and HSCs, making a paracrine effect in vivo in our
model unlikely (Supplementary Figure 2). Finally, the
absence of HSC activation by -smooth muscle actin
immunohistochemistry (Figure 4E), the complete lack of
fibrosis on histology, and the missing effect of co-cultured
Notch1-deficient HSCs on in vitro angiogenesis (Figure 4F)
make HSC as drivers of the vascular remodeling in our
model unlikely.
Interruption of Notch1 Signaling Leads to
Regulation of the LSEC Receptors EphrinB2/
EphB4
Prior studies have delineated the role of Notch
signaling in functional vessel patterning and differentia-
tion in developmental angiogenesis8; however, Notch sig-
aling in LSECs of the adult liver is less well defined.
xpression analysis of Notch members in isolated LSECs
nd hepatocytes from WT and KO animals showed 7-fold
ncreased Notch1 mRNA levels in WT LSECs versus hepa-
tocytes (Figure 5A and Supplementary Figure 3B). Dele-
tion was almost complete as early as 3 days after pIpC
injection (Figure 5A and Supplementary Figure 3B). To
assess how Notch1 deletion induces vascular remodeling,
we analyzed genes known to promote vascular growth and
maturation. We found a significant and persistent down-
regulation of Dll4, as well as the receptor tyrosine kinase
EphrinB2 in LSECs, whereas angiopoietins, fibroblast
growth factors, VEGF, and VEGF-receptor 2 were not
regulated after Notch1 deletion (Figure 5B and Supple-











































April 2012 NOTCH1 IN HEPATIC MICROCIRCULATION 973(Tek) was down-regulated significantly only after 12
weeks, which might be a secondary effect after vascular
remodeling and development of NRH. A decrease of
EphrinB2 after Notch1 KO could not be detected by
immunohistochemistry; however, EphB4 was strongly up-
regulated in the endothelial lining of the sinusoids in
comparison with controls (Figure 5C).Notch1 KO Mice Develop Hepatic
Angiosarcomas
Interestingly, long-term experiments revealed
spontaneous development of hepatic tumors in Notch1
KO mice 50 weeks after pIpC injection with a penetrance
of 86%, whereas none of the Cre- mice showed any phe-
notypical changes (Figure 6A). Histologic assessment fur-
ther characterized these tumors as angiosarcomas with
highly dysplastic endothelial cells as confirmed by CD34
staining (Figure 6B and C).
Discussion
Mammalian endothelial cells display remarkable
heterogeneity in structure and function in different or-
gans.1 The molecular determinants of the organ-specific
henotype of endothelial cells are poorly understood. We
nvestigated the role of Notch1 receptor, which is known
o regulate arteriovenous differentiation during embryo-
enesis, in the hepatic endothelium of adult mice. Our
ndings provide loss-of-function evidence that Notch1 is
equired for vascular homeostasis of hepatic sinusoids by
nducing quiescence and differentiation of LSECs. Dis-
uption of the Notch1 pathway leads to intussusceptive
ngiogenesis, LSEC proliferation, loss of fenestrae, sinu-
oidal capillarization with portal hypertension, and, even-
ually, malignant transformation (Figure 7).
The hepatic microcirculation is composed of highly
ifferentiated endothelial cells with distinct gene and pro-
ein expression profiles as well as a distinct phenotype
haracterized by fenestrations, sieve plates, and lack of a
asement membrane.1,25 In the adult, LSECs acquire a
quiescent, nonangiogenic state. Nevertheless, LSECs re-
tain considerable proliferation and growth potential,
which is activated during physiological processes such as
liver regeneration as well as in pathologic conditions such
as tumor angiogenesis in hepatocellular carcinoma. Sig-
naling pathways that activate LSECs (ie, VEGF, placental
4™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
Figure 4. Phenotypic changes in the liver are not hepatocyte- or HSC-
driven. (A) Notch1lox/lox mice were crossed with mice carrying Cre under
ontrol of the albumin promoter (AlbCre KO). Southern blot analysis of
iver homogenates in 8-week-old mice proved successful recombination
Notchdel). The remaining Notchlox band reflects mainly the nonhepato-
cyte cell population in the liver homogenate. (B) The average amount of
BrdU-positive hepatocytes and LSECs in 10 high-power fields in liver
sections of AlbCre KO mice (16 weeks) was assessed and showed no
difference in proliferation rate (n 5 animals per genotype). (C) Morphol-
ogy of vascular casts from 12-week-old AlbCre KO mice was normal
(bar  50 m). (D) Cell viability of transformed murine LSECs assessed
y MTT assay and tube length formation assessed by tube formation
ssay showed no significant difference after being treated for 24 hours
ith conditioned fetal bovine serum (FBS)-free media derived from iso-
ated primary hepatocytes from either WT or MxCre Notch1lox/lox (KO)
mice (3 independent experiments in duplicates). (E) Quantification of
activated HSC by -smooth muscle actin (-SMA) immunohistochem-
istry showed no difference between WT and MxCre Notch1lox/lox (KO)
mice (12 weeks after pIpC injection). (F) Tube formation of murine LSECs
co-cultured with isolated HSCs (3 days after pIpC injection) was not




































974 DILL ET AL GASTROENTEROLOGY Vol. 142, No. 4growth factor) have been studied extensively.7 However,
signals that induce and maintain quiescence and differ-
entiation of LSECs are poorly understood. An important
signaling pathway for differentiation in endothelial and
vascular smooth muscle cells during vascular develop-
ment is Notch, which controls endothelial cell migration,
arteriovenous specification, and regulation of blood vessel
sprouting and branching during normal and pathologic
angiogenesis.8,26 KO mice that lack components of the
otch pathway have severe vascular defects and die in
tero.26 There are only limited studies on the function of
Notch in the adult and differentiated vasculature. Carlson
et al27 reported that endothelial expression of constitu-
ively active Notch4 elicits reversible arteriovenous mal-
ormations in the liver, uterus, and skin of adult mice.
he precise molecular function of Notch signaling in the
ascular specification remains unknown. Several develop-
ental studies have shown that Notch modulates the
EGF-VEGF-receptor signaling and Ephrin signaling in
ndothelial cells, which are crucial for proliferation, mi-
ration, differentiation, and endothelial cell survival.26 In
solated LSECs of our Notch1 KO mice, we have found a
down-regulation of Dll4, Tek, and EphrinB2 (Figure 5). Tek
is an important receptor tyrosine kinase in differentiated
endothelial cells and has been shown to regulate vessel
maturation and quiescence.28 The role of the tyrosine
kinase receptor EphB4 and its ligand ephrinB2 in the ahepatic microcirculation is not well defined. Up-regula-
tion of EphB4 expression was detected in hepatic sinusoi-
dal vessels during vascular remodeling in rats after carbon
tetrachloride–induced liver injury or bile duct ligation.22,29
Das et al29 showed that ephrinB2/EphB4 signaling pro-
motes chemotaxis of LSECs through a pathway that in-
volves extracellular regulated kinase (Erk), Kruppel-like
factor 2, and VEGF. In gain- and loss-of-function experi-
ments, Notch, through the ephrinB2/EphB4 pathway, re-
cently was found to be the molecular regulator in the
balanced growth of arteries and veins during early devel-
opment.30,31 Notch signaling controls this equilibrium
by regulating vascular size and by promoting arterial
differentiation, thereby dictating the ratio of arterial to
venous ECs. EphrinB2/EphB4 signaling regulates this
balance by sorting differential ECs into the respective
vessels.30,31 Hence, our study in the liver microcircula-
ion of adult mice supports this concept, that Notch
hrough ephrinB2/EphB4 signaling regulates vascular
ifferentiation and size.
Interestingly, SEM analysis in our study revealed mor-
hologic characteristics of an alternative form of angio-
enesis after Notch1 KO, termed intussusceptive angiogenesis
Figure 2). Generation of new vessels by intussusception is
unique mechanism of vascular growth that allows rapid
xpansion and remodeling of microvessels. This mode of
Figure 5. Interruption of Notch1
signaling leads to LSEC activation
through regulation of EphrinB2/
EphB4. (A) Quantitative reverse-
transcription polymerase chain re-
action analysis of Notch1 mRNA
in isolated LSECs, hepatocytes,
and HSCs of WT and KO mice
relative to the amount in WT
LSECs after normalization to
Rpl19. (B) mRNA expression of
Dll4, Efnb2, Vegfr2, and Tek from
isolated LSECs (n indicated below
the plots). Values are normalized
to Rpl19 expression. Bars show
mean with standard error of the
mean. (C) EphB4 immunohisto-
chemistry showed increased
staining in the LSECs of KO mice
(bar  100 m). All analyses
were performed with mice 12






































April 2012 NOTCH1 IN HEPATIC MICROCIRCULATION 975developing lungs,32 but also has been found to contribute
n physiological angiogenesis during liver regeneration as
ell as in pathologic angiogenesis in chronic liver disease
nd hepatocellular carcinoma.7,33,34 The molecular signal-
ng regulating intussusceptive angiogenesis remains un-
lear and might involve several angiogenic pathways such
s the VEGF and mammalian target of rapamycin path-
ays.34,35 Our study suggests that Notch signaling is an-
ther, albeit negative, regulator and that absence of the
otch1 receptor in LSECs induces this specific form of
ngiogenesis and vascular remodeling.
Portal hypertension is a known complication in patients
ith NRH. In fact, NRH is the most frequent cause of
ntrahepatic, noncirrhotic portal hypertension in the West-
rn world.17 In our murine model, we interpret the observed
increase in portal pressure even before the onset of NRH as
a result of increased intrahepatic resistance induced by fric-
tional forces of the remodeled microcirculation and in-
creased branching points on the blood, which from a fluid
dynamics perspective is a visco-elastic fluid. Such a nonideal
Figure 6. Notch1 KO mice develop hepatic angiosarcomas. (A) Mac-
oscopic images of livers 50 weeks after pIpC injection, showing cavern-
us, blood-filled tumors in the KO. (B) H&E and (C) CD34 immunohisto-
hemical staining of hepatic angiosarcomas in KO mice 50 weeks after
IpC injection (bar  200 m). Black arrows indicate endothelial cells
with highly dysplastic nuclei.fluid is subject to a complex rheology with frictional forcescaused by shear stress through vessel convergence, diver-
gence, varying diameters, turns, and surface irregularities.
Two recent independent computational fluid dynamic stud-
ies have confirmed increased shear force in vascular beds
with intussusceptive angiogenesis in vivo and in silico.36,37
However, we cannot exclude that increased splanchnic in-
flow and the nodular transformation of the liver paren-
chyma alsomight contribute to the increased portal pressure
in Notch1 KO mice.
Notch1 has been shown to be an oncogene in many solid
tumors and in leukemia. Depending on the tissue type,
Notch1 also rarely can function as a tumor-suppressor gene
Figure 7. Time line of phenotypic changes after Notch1 KO. In adult
liver Notch1 is required to maintain endothelial quiescence and differen-
tiation. Disruption of Notch1 signaling induces intussusceptive angio-
genesis, proliferation, and portal hypertension, eventually leading to si-











































976 DILL ET AL GASTROENTEROLOGY Vol. 142, No. 4(ie, in squamous cell carcinoma of skin and lung). Recently,
blockade of Dll4 as well as loss of heterozygosity of Notch1
led to vascular tumors in animals.38,39 In our model, we
observed persistent and cell autonomous LSEC prolifera-
tion, dedifferentiation, and eventually malignant transfor-
mation (Figure 7). Therefore, our findings of spontaneous
development of hepatic angiosarcoma establish Notch1 also
as a tumor-suppressor gene in LSECs.
Thus, the present study identifies Notch1 as an impor-
tant signaling pathway in LSECs that governs vascular
structure and function in the liver, regulates intussuscep-
tive angiogenesis, and acts as an endothelial tumor-sup-
pressor gene.
Supplementary Material
Note: To access the supplementary material
accompanying this article, visit the online version of
Gastroenterology at www.gastrojournal.org, and at doi:
10.1053/j.gastro.2011.12.052.
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977.e1 DILL ET AL GASTROENTEROLOGY Vol. 142, No. 4Supplementary Figure 1. Schematic representation of intussuscep-
ive angiogenesis. Graphic diagram showing the 3-dimensional process
enerating new vessels by intussusceptive angiogenesis. Protrusions of
pposing endothelial cells into the vascular lumen establish interendo-
helial contacts. The newly formed pillar increases in girth and leads to
onsecutive splitting of the vessel into 2 daughter vessels. Modified
rom Burri PH, Hlushchuk R, Djonov V. Intussusceptive angiogenesis:
ts emergence, its characteristics, and its significance. Dev Dyn 2004;
31:474–488 and Makanya AN, Hlushchuk R, Djonov VG. Intussus-
eptive angiogenesis and its role in vascular morphogenesis, pattern-
ng, and remodeling. Angiogenesis 2009;12:113–123.
Supplementary Figure 2. mRNA expression of growth factors from d
is not increased in isolated LSECs and HSCs from KO mice 12 weeks aft
from KO mice 12 weeks after pIpC injection. (C) mRNA amount of trans
ice early and late after pIpC injection. (D) mRNA amount of the growthifferent hepatic cell compartments. (A) mRNA amount of Hgf relative to Rpl19
er pIpC injection. (B) mRNA amount of Vegf is not increased in isolated HSCs
forming growth factor  1 (Tgfb1) is not increased in isolated HSCs from KO
factors Vegf, Angpt1, Angpt2, Fgf1, and Fgf2 are not increased in isolated
hepatocytes from KO mice 12 weeks after pIpC injection. All bars show mean with standard error of the mean (n is indicated below the plots).
April 2012 NOTCH1 IN HEPATIC MICROCIRCULATION 977.e2Supplementary Figure 3. mRNA expression from isolated LSECs, hepatocytes, and HSCs of WT and KO mice. (A) Relative expression of mRNA
ofNotch2 andNotch4 from LSECs, hepatocytes (HCs), and HSCs isolated 12 weeks after pIpC injection from WT and KO mice. Shown is the amount
relative to LSEC WT expression after normalization to Rpl19. Notch3 had a very low expression both in LSECs and HCs of WT and KO animals and
is not shown. (B) Relative expression of mRNA of Notch1 from LSECs, HCs, and HSCs isolated 3 days after the first pIpC injection from WT and KO
mice. Shown is the amount relative to LSEC WT expression after normalization to Rpl19. (C) mRNA expression of Dll4, Efnb2, Tek, and Vegfr2 from
isolated LSECs 3 days after pIpC injection. Values are normalized to Rpl19 expression. All bars show mean with standard error of the mean (n is
indicated below the plots).
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Abstract
Background & Aims: Nodular regenerative hyperplasia (NRH) is a rare liver
disease characterized by small regenerative nodules without fibrosis and can
cause portal hypertension. Aetiology and pathogenesis of NRH remain
unclear. We have recently shown that Notch1 knockout induces NRH with
portal hypertension through vascular remodelling in mice. The aim of this
study was to analyse histological and clinical data of NRH patients and to
explore if the endothelial pathways identified in our NRH mouse model are
also regulated in human NRH. Methods: Patients were identified retrospec-
tively from the pathology database. Clinical and laboratory patient data were
retrieved. mRNA expression was measured in liver biopsies from a subset of
NRH patients. Results: Diagnosis of NRH was confirmed in needle biopsies
of 51 patients, including 31 patients with grade 1, 12 patients with grade 2
and 8 patients with grade 3 NRH. Grade 3 nodularity significantly correlated
with the presence of portal hypertension: 50% of the patients with grade 3
NRH vs. 6.5% with grade 1 (P = 0.0105). mRNA expression analysis in liver
biopsies from 14 NRH patients and in primary human sinusoidal endothelial
cells revealed downregulation of identical genes as in the murine NRH
model, which are implicated in vascular differentiation: Notch1, delta-like 4
(Dll4) and ephrinB2. Conclusions: In this large NRH needle biopsy cohort,
we demonstrated that advanced nodularity correlates with presence of portal
hypertension. Downregulation of the endothelial signalling pathways Dll4/
Notch1 and ephrinB2/EphB4 supports the hypothesis that human NRH is
caused by a sinusoidal injury providing first insights into the molecular path-
ogenesis of this liver condition.
Nodular regenerative hyperplasia (NRH) is a rare liver
disease characterized by diffuse nodular transformation
of the hepatic parenchyma into small regenerative nod-
ules. Typically mild or no fibrosis is observed, distin-
guishing these lesions from cirrhosis (1, 2). Dilated
sinusoids are found in internodular regions, whereas in
the nodules they are usually narrow (3). Only histology
showing these features allows the diagnosis of NRH.
Clinical presentation varies from patient to patient.
The course of disease is often asymptomatic and liver
function is usually preserved (2, 4). In case of a symp-
tomatic presentation, the primary clinical manifestation
Liver International (2013)
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is portal hypertension complicated by variceal bleeding,
splenomegaly and ascites (5–8).
NRH has been reported to occur in association with
rheumatological disorders, haematological malignancies
and other conditions (2, 9). Several drugs have also been
associated with the development of NRH, among which
azathioprine is the most frequent reported drug (2, 8–
10). Originally, it has been suggested that NRH is
caused by obliterative changes such as thromboembolic
events leading to compromised hepatic blood flow with
subsequent atrophy in ischaemic regions and reactive
hyperplasia in well-perfused regions (2). Many of the
reported associations can be explained by this causal
concept as they all can be traced back on the common
feature of heterogeneous hepatic blood supply. How-
ever, circulatory impairment in the hepatic microcircu-
lation in the absence of thromboembolic events has also
been reported (6, 7, 11, 12). In this context, we have
previously shown that knockout of the receptor Notch1
in liver sinusoidal endothelial cells induces NRH with
portal hypertension through vascular remodelling and
capillarization of the liver microvasculature (13, 14).
Molecular analysis in these NRH mice showed that the
vascular changes are mediated through the endothelial
ephrinB2/EphB4 pathway supporting the hypothesis
that the primary event in NRH is a sinusoidal endotheli-
opathy preceding hepatocyte proliferation (2).
The aim of this study was to analyse histological, clin-
ical and biochemical features of NRH patients as well as
to determine if the endothelial genes found in our
mouse model are also regulated in human NRH.
Material and methods
Patient selection
In this retrospective study, we searched the liver biopsy
database of the Pathology Institute of the University
Hospital Basel for entries between 1996 and 2011
containing the words nodular regenerative hyperplasia.
The database comprises all liver biopsies that were per-
formed at the University Hospital Basel or biopsies sent
to the Pathology Department for second opinion.
Patients who underwent a liver biopsy within the study
time were included if their liver biopsy showed histolog-
ical features exclusively of NRH without further features
of additional chronic liver disease. The reason for liver
biopsy in the NRH patients was unclear elevation of
liver function tests after negative hepatopathy screening.
Clinical records were retrieved for the identified NRH
patients. To complete the medical history for patients,
general practitioners or the attending doctor was also
contacted. Patients with concomitant liver disease were
excluded.
Histological analysis
The diagnosis of NRH was based on histological assess-
ment of needle biopsies. Liver biopsies were stained with
haematoxylin-eosin, reticulin (Novotny) and Sirius red.
All biopsies were reassessed for nodularity, fibrosis and
sinusoidal dilatation by LTe, an expert liver pathologist
at the University Hospital Basel. NRH was diagnosed on
haematoxilyn-eosin, Sirius red and reticulin staining,
according to well-established criteria in liver biopsies,
including liver cell nodularity as well as the presence of
regenerating liver cell plates, surrounded by compressed,
atrophic liver cell plates in the absence of/or with mini-
mal fibrosis (15, 16). Nodular hyperplasia was classified
into grade 0–3. Briefly, absent nodularity was rated as
grade 0; mild, moderate and prominent nodularity as
appearing on H&E and reticulin staining were graded
with 1, 2, and 3 respectively. The nodularity grading also
takes into account the extent of nodular transformation
in the biopsy. Sinusoidal dilation was assessed as present
or absent. Several weeks after the first histological exam-
ination, livers were examined a second time to confirm
the NRH diagnosis and nodularity grading as well as to
assess the intraobserver variability.
Laboratory tests
Data for the following laboratory tests were retrieved:
alanine aminotransferase (ALT), aspartate aminotrans-
ferase (AST), gamma glutamyl transferase (GGT), alka-
line phosphatase (ALP), platelet counts, total bilirubin,
albumin and the international normalized ratio (INR).
Tests were usually performed on the day of the biopsy,
otherwise test results within a period of one month
prior or after the biopsy were used.
Assessment of portal hypertension
Presence of portal hypertension was assigned if any of
these conditions were observed: hepatic venous pressure
gradient (HVPG) >10 mmHg; ascites, splenomegaly or
dilated portal vein (>13 mm in transverse diameter);
oesophageal or gastric varices or portal-hypertensive
gastropathy assessed by endoscopy. Isolated splenomeg-
aly in patients with an underlying primary disease such
as haematological malignancies was not included as a
criterion of portal hypertension.
Immunohistochemical studies
For CD34 immunohistochemistry, 3–5 lm paraffin-
embedded liver sections were stained using the
automated Benchmark XT system (Ventana Medical
Systems, Tucson, AZ) with the commercially available
prediluted monoclonal antibody (790-2927, Ventana)
and the Enhanced DAB Detection Kit (Ventana).
RNA extraction and quantitative RT-PCR
Upon written informed consent, 14 patients agreed to
donate a second liver biopsy for research purposes taken
immediately through the same coaxial needle as the
Liver International (2013)
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diagnostic liver biopsy. The protocol was approved by
the ethical commission of Basel. Supplementary Table 1
summarizes detailed information on these 14 patients.
As controls (n = 10), hepatitis C patients showing a
Metavir activity/fibrosis score A1F0 or A1F1 were used.
Additional controls included biopsies from patients
with cirrhosis (n = 7) and focal nodular hyperplasia
(FNH, n = 8). RNA was extracted from human liver tis-
sue and from liver sinusoidal endothelial cells (LSEC)
using TRIzol reagent (Invitrogen, Basel, Switzerland)
according to the manufacturer’s instruction. RNA was
reverse transcribed with Moloney Murine Leukaemia
Virus Reverse Transcriptase (Promega Biosciences, Wal-
lisellen, Switzerland) in the presence of random primers
(Promega) and deoxynucleoside triphosphates. SYBR
green-based real-time polymerase chain reaction (SYBR
green PCR master mix; Applied Biosystems, Foster City,
CA) was performed. Intron-spanning primers were
designed for Rpl19, Notch1, Hes1, EfnB2, EphB4, Dll4
and TEK tyrosine kinase, endothelial (Tek) (Supple-
mentary Table 2). All reactions were carried out in
duplicate on an ABI 7500 Fast Real-Time PCR System
(Applied Biosystems). Messenger RNA (mRNA) expres-
sion levels of the transcripts were normalized to RPL19
using the DCt method.
Cell culture
Isolated primary human LSEC (ScienCell Research
Laboratories, Carlsbad, CA, USA) were used between
passages 2 and 6. LSEC were cultured in endothelial cell
medium (ScienCell) supplemented with 5% foetal bovine
serum, 1% endothelial growth supplement (ScienCell)
and 1% penicillin/streptomycin (ScienCell). For mRNA
analysis, cells were serum-starved overnight and were
then treated with the c-secretase inhibitor N-[N-(3,5-di-
fluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester
(DAPT, Sigma, St. Louis, MO) for 24 h, with azathio-
prine (Pro Concepta Zug AG, Zug, Switzerland) 150 lM
for 24 h or with methotrexate (Pfizer AG, Z€urich,
Switzerland) 1 or 10 lg/mL for 24 h respectively.
Statistical analysis
Diagrams, unpaired Student’s t-tests and Fisher’s exact
test were performed using GraphPad Prism version 4.00
for Macintosh (GraphPad Software, San Diego, CA,
www.graphpad.com). Kappa statistic was calculated to
determine the intraobserver variability in the evaluation
of histological NRH nodularity grading.
Results
Patient demographics
Fifty-one patients with a confirmed histological diagno-
sis of NRH were identified. The computer search of the
pathology report database for NRH resulted in 221
patients. However, 127 patients had to be excluded as
the biopsy was performed externally and sent to the
Pathology Department of the University Hospital Basel
for a second opinion. Liver biopsies with less than 5
portal tracts or liver biopsies too much fragmented for a
reliable assessment of the lobular architecture were
excluded, which was the case in 6 patients. A further 25
patients were eliminated for not meeting the criteria for
NRH. Another 12 cases were excluded because of other
or concomitant causes of liver disease (i.e. primary
biliary cirrhosis, chronic viral hepatitis, Budd-Chiari
syndrome), leaving 51 patients with a confirmed diag-
nosis of NRH in the study. These 51 patients had percu-
taneous biopsies except one patient with a transjugular
biopsy only (total of three passes allowing reliable diag-
nosis of NRH).
This study group included 28 men and 23 women
with a mean age at diagnosis of 49 years (range
9–75 years) (Table 1). Among the 51 NRH patients, 24
were not reported to have any disease, condition or drug
related to NRH. The associations found in the remain-
ing 27 patients were classified into four groups: rheuma-
tological disorders, haematological malignancies, drugs
and miscellaneous (Table 1).
Liver function tests and presence of portal hypertension
For 46 patients, liver biochemical tests were available
and retrieved (Fig. 1). The majority of patients showed
only minor abnormalities. However, increased levels
Table 1. Patient characteristics and conditions associated with
nodular regenerative hyperplasia
Characteristics Values











Systemic lupus erythematosus 2 (4%)
Rheumatoid arthritis 1 (2%)
Haematological disorders
Hodgkin’s lymphoma 1 (2%)
Osteomyelofibrosis 1 (2%)
Acute lymphoblastic leukaemia 1 (2%)
Chronic myelogenous leukaemia 1 (2%)





Antimitochondrial antibody seropositivity 1 (2%)
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(1.5 times the upper limit of normal) were found for
alanine aminotransferase in 21 patients (41.2%), for
gamma glutamyl transferase in 30 patients (58.8%) and
for alkaline phosphatase in 8 patients (15.7%). Serum
albumin was decreased in patients with grade 3 NRH
compared to grade 1 NRH (P = 0.0231).
Imaging studies were available for 37 patients, of
which 4 patients additionally underwent assessment of
hepatic venous pressure. Nine patients (17.6%) pre-
sented with clear signs of portal hypertension: oesopha-
geal varices, ascites, splenomegaly, portal-hypertensive
gastropathy and/or widened portal vein (Table 2). Vari-
ces were observed in six patients identified with portal
hypertension. Of 4 patients in whom HVPG measure-
ment was performed, 3 had a high pressure gradient
(>10 mmHg). The fourth patient showed normal HVPG
(<6 mmHg) most probably explained by collateral circu-
lation observed on angiography during HVPG measure-
ment in wedged position, but had otherwise clear signs
of portal hypertension (varices, splenomegaly, portal-
hypertensive gastropathy, ascites). In total, 15 patients
had an upper gastrointestinal endoscopy of whom 7
patients showed signs of portal hypertension (Table 2).
Association between histological grading and presence of
portal hypertension
Nodularity of the liver parenchyma was classified into
grade 1, grade 2 and grade 3 depending on the degree of
nodular transformation. Among the 51 patients diag-
nosed with NRH, grade 1, grade 2 and grade 3 were
observed in 31 (60.8%), 12 (23.5%) and 8 (15.7%)
patients respectively. In the biopsies showing nodular
regeneration grade 1 (Fig. 2A), nodular transformation
could be identified focally in the liver biopsy, whereas in
a biopsy of grade 2 (Fig. 2B), nodularity was found to a
larger extent. Grade 3 (Fig. 2C) was assigned to biopsies
with a very distinct nodular transformation found
throughout the biopsy specimen. Sinusoidal dilatation
was found in all patients with grade 3 NRH, in 75.0% of
those with grade 2 NRH and in 58.1% of patients having
grade 1 nodular transformation. A second blinded
microscopic evaluation of the biopsies showed an excel-
lent agreement for the evaluation of NRH nodularity
staging with a kappa coefficient of 0.931. The mean
percentage agreement between the first and second eval-
uation was 96.2%. Presence of portal hypertension was
associated with advanced degree of nodularity, namely
Table 2. Assessment of portal hypertension
Nodularity Patient # Signs of portal hypertension
3 a HVPG 22 mmHg, ascites, splenomegaly,
portal-hypertensive gastropathy
b Ascites, dilated portal vein
c Ascites, splenomegaly




f Varices, ascites, splenomegaly, dilated
portal vein
g HVPG 13 mmHg, varices, splenomegaly
1 h Varices, splenomegaly, portal-hypertensive
gastropathy, dilated portal vein
i HVPG 14 mmHg, varices, splenomegaly
Fig. 1. Liver function tests at the time of biopsy in NRH patients. Liver function tests, platelet counts, total bilirubin, albumin and INR in NRH
patients according to NRH grading (N1-3). Each circle represents an individual patient, bars represent mean. *P < 0.05, **P < 0.01.
Liver International (2013)
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd4
Notch/Ephrin signalling in patients with NRH Rothweiler et al.
in the group of patients diagnosed with grade 3 NRH,
portal hypertension was reported in 50% (P = 0.0105,
grade 3 vs. grade 1, Fisher’s exact test). In contrast,
portal hypertension was identified in only 25% of the
cases with grade 2 NRH and in 6.5% of patients with
grade 1 NRH (Table 3).
CD34 expression and histological features of NRH
In normal liver, CD34 is absent in hepatic sinusoids
except for periportal LSEC (Fig. 3A) (17). However,
CD34 has been shown to be a marker of sinusoidal
capillarization and is upregulated in chronic liver
Table 3. Presence of portal hypertension







Fig. 2. Histological assessment of liver biopsies from NRH patients by Novotny staining showing grade 1 (A, mild nodularity), grade 2 (B,
moderate nodularity) and grade 3 (C, severe nodularity) nodularity. Arrows indicate compressed regions at the periphery of nodules. Note
dilated sinusoids in grade 3 NRH biopsy. Original magnification: left panel 509, right panel 1009.
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disease (18). Analysis of CD34 expression in 47/51
(92.2%) patients showed that in NRH biopsies with
advanced nodularity, CD34 positivity was more pro-
nounced in selected patients: CD34 was expressed to a
greater extent in compressed regions which are noticed
at the periphery of nodules, where sinusoids and hepatic
plates are compressed by the regenerative, hypertrophic
hepatocytes (Fig. 3B). We identified enhanced sinusoi-
dal CD34 expression in four patients with grade 3
nodularity and in one patient with grade 2 nodularity.
Interestingly, increased CD34 expression was observed
predominantly in patients presenting with signs of
portal hypertension (4 out of the 5 cases had portal
hypertension). Notably, the patient with NRH grade 2
and upregulated CD34 expression was also found to
have portal hypertension. NRH patients with grade 1
nodularity showed no increased CD34 expression in
comparison to controls.
Gene expression analysis in NRH patients
We have previously shown that endothelial dysfunction
is the primary event leading to development of NRH in
mice (13, 14). In this NRH mouse model, we have
identified dysregulation of the endothelium-specific
signalling pathways Dll4/Notch1 and ephrinB2/EphB4,
which are known to regulate endothelial differentiation
and vascular remodelling. To explore if these endothelial
pathways are also dysregulated in patients diagnosed
with NRH, we have performed expression analysis in
human tissue from liver biopsies. For 14 of our NRH
patients, a second liver biopsy specimen for research
purposes was available (detailed information see Sup-
plementary Table 1).
As control group, we have chosen patients with mini-
mally active chronic hepatitis C (A1F0 and A1F1) as
liver biopsies from healthy subjects were not available.
Low fibrosis scores were selected to match NRH biopsies
in terms of no to minimal fibrosis. Liver biopsies from
patients with FNH and cirrhosis were used as additional
control groups to assess specific expression of Dll4/
Notch1 and ephrinB2/EphB4 in liver diseases associated
with regenerative processes, vascular abnormalities and/
or portal hypertension. Notably, the control group with
cirrhosis patients showed a similar amount of portal




Fig. 3. Changes in endothelial gene expression in liver biopsies from NRH patients. Expression of CD34 in NRH livers with grade 1 nodularity
(A) and with advanced grade 3 nodularity (B). CD34 immunohistochemistry with positive endothelial cells at the periphery of nodules
(arrows). Original magnification: 1009 (A, B left panel) and 509 (B right panel). (C) Gene expression analysis for Notch1, Hes1, Dll4, eph-
rinB2, EphB4 and Tek in 14 NRH patients in comparison to controls (n = 8), to cirrhotic patients (n = 7) and to patients with focal nodular
hyperplasia (FNH, n = 8).
Liver International (2013)
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd6
Notch/Ephrin signalling in patients with NRH Rothweiler et al.
cirrhotics vs. 2/14 NRH patients with portal hyperten-
sion). In NRH patients, mRNA expression of the
Notch1 receptor, its ligand Dll4, the EphB4 receptor
and its ligand ephrinB2 as well as Tek were significantly
reduced compared to control patients (Fig. 3C). Notch1
was also found to be downregulated in other conditions
with vascular remodelling and sinusoidal capillarization
such as cirrhosis and FNH. However, downregulation of
Dll4 and ephrinB2 was specific for NRH and was not
regulated in cirrhosis and FNH (Fig. 3C).
One limitation of human studies is the impracticality
to isolate pure LSEC from NRH liver biopsies. To over-
come this drawback, we performed complementary
experiments using isolated primary human LSEC from
resected livers. LSEC incubated with the gamma-secre-
tase inhibitor DAPT, to inhibit Notch signalling, con-
firmed regulation of Dll4 and ephrinB2 (Fig. 4A). The
same gene signature was found in primary human LSEC
treated with azathioprine, which is known to induce
NRH in patients (Fig. 4B). In contrast, methotrexate,
which is an antimetabolite like azathioprine but not
associated with NRH, did not downregulate the expres-
sion of Dll4/Notch1, Tek or ephrins (data not shown).
Discussion
In this large liver biopsy-based NRH cohort, we investi-
gated the relationship between histological grading, clin-
ical presentation and molecular changes with specific
attention to endothelial involvement in this disease.
This study established a correlation between portal
hypertension and degree of liver nodularity in NRH
patients. Downregulation of the endothelial specific
genes Notch1, Dll4, ephrinB2 and Tek supports the
hypothesis that human NRH is caused by an endotheli-
opathy of the hepatic microcirculation (Fig. 5).
The exact pathogenesis of NRH remains unclear. One
of the pathological concepts describes NRH as a result
of a reactive hyperplastic response of hepatocytes
induced by impaired hepatic blood flow possibly initi-
ated by vascular obliteration. In 1856, the pathologist
Rudolf Virchow postulated that thrombus formation is
causally related to abnormalities in blood flow (stasis),
hypercoagulability of the blood and endothelial injury
(19). In keeping with Virchow’s concept, all three cate-
gories can be involved in the pathogenesis of NRH by
causing impaired hepatic blood flow. Vascular obstruc-
tion can occur at the sinusoidal level or at the level of
portal vein branches. In addition, in the literature there
are many cases describing NRH in association with dis-
orders affecting the vasculature such as Felty’s syndrome
(20), polyarteritis nodosa (21), rheumatoid vasculitis
(22) or hereditary haemorrhagic teleangiectasia (23), all
supporting the concept that vascular lesions are the trig-
ger towards the common pathological mechanism of
impaired hepatic blood flow. However, only few studies
addressed the role of sinusoidal endothelial cells in
NRH. In a murine NRH model, we have recently shown
that deletion of the receptor Notch1 leads to disruption
of LSEC homoeostasis leading to persistent LSEC
proliferation, intussusceptive angiogenesis, loss of
fenestrae, capillarization of the hepatic microcirculation
and eventually portal hypertension (14). Hepatocyte
proliferation and nodular transformation of the liver
(A)
(B)
Fig. 4. Gene expression analysis in isolated human liver sinusoidal endothelial cells (LSEC). (A) Gene expression analysis after incubating
LSEC for 24 h with the Notch inhibitor N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester (DAPT). (B) Endothelial genes
are downregulated in LSEC treated with azathioprine for 24 h. Data represent three individual experiments performed in duplicates.
Mean+SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
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parenchyma were secondary events only following
vascular remodelling and led to development of
pronounced NRH in these mice. These experimental
findings suggest that NRH is an adaptive response to
impaired vascular function in the liver. The process of
vascular dedifferentiation in this model was found to be
mediated by Notch, ephrin and Tek signalling, all of
which are key players in LSEC differentiation and quies-
cence (14). In our murine NRH model, we have shown
that these endothelial signalling pathways are required
for vascular homoeostasis and normal function of the
hepatic sinusoids by inducing quiescence and differenti-
ation of LSEC and that disruption of Notch1 leads to
NRH and portal hypertension. Here, we confirm for the
first time specific regulation of these endothelial signal-
ling pathways in human liver biopsies from NRH
patients and in vitro in isolated primary human LSEC.
Notch1 signalling has been extensively studied in vascu-
lar development and has been shown to mediate cell-
autonomous regulation of vessel sprouting, branching
and vascular diameter in endothelial cells (24, 25). Simi-
lar to our NRH mouse model, deregulated Notch signal-
ling has been shown to promote pulmonary arterial
hypertension in humans and mice through vascular
remodelling and increased vascular resistance (26).
Notch1 has emerged as a critical mediator in multiple
processes of the angiogenic response such as orchestra-
tion of tip/stalk cell specification during angiogenesis,
spatial restriction of the VEGF response and determina-
tion of the arterial or venous cell fate specification (27,
28). Furthermore, ephrinB2 has been shown to be a
direct Notch target (29). EphrinB2 and its receptor
EphB4 control segregation and sorting of arterial and
venous endothelial cells allowing remodelling and matu-
ration of the primitive capillary networks into arteries
and veins (30, 31). In the liver vasculature, ephrinB2/
EphB4 signalling has been reported to regulate micro-
vascular structure during remodelling in chronic liver
disease (32). Moreover, ephrinB2/EphB4 and Notch
loss-of-function mutants show arteriovenous malforma-
tions (33, 34). Considering the multifactorial aetiology
of NRH, other pathways could also be involved in the
pathogenetic process of this disease. Such a candidate
could be Angiopietin-1 (Ang-1), the major agonist for
Tek. Tek is involved in vessel maturation and quiescence
and has very recently been shown to potentiate the Dll4/
Notch signalling leading to vascular quiescence (35). In
a transgenic mouse model, it has been shown that dele-
tion of Ang-1 is embryonically lethal because of vascular
abnormalities. In contrast, deletion of Ang-1 after E13.5
did not result in an overt phenotype suggesting a dis-
pensable role for Ang-1 in adult, quiescent vasculature
(36). Of note, in our previous murine NRH study, no
significant differences in Ang-1 and Ang-2 expression
were observed in hepatocytes isolated from NRH mice.
On the other hand, the endothelial receptor Tek was
significantly lower expressed in NRH mice compared to
wildtype mice, which is in line with the findings in the
human NRH biopsies (14). In summary, these preclini-
cal studies highlight the pivotal role of the Notch
pathway and the ephrin signalling in angiogenesis,
endothelial differentiation and vascular homoeostasis.
Analysing Notch1 expression in our liver biopsies from
NRH patients, FNH patients and patients with cirrhosis
showed an overall downregulation when compared to
controls. Strikingly, Dll4 and ephrinB2 were found to be
regulated in NRH patients only but not in patients with
liver cirrhosis or FNH. The discovery of such a restricted
gene expression pattern was unexpected as the analysed
NRH patients present different aetiologic factors. The
specific downregulation of Dll4 and ephrinB2 in our
patient cohort (comprising different aetiologies of
NRH) indicates that the underlying mechanism in these
patients can be attributed to an endotheliopathy medi-
ated through the common final pathway of Dll4/Notch1
and ephrinB2/EphB4 signalling. These molecular find-
ings are in line with a recently published murine NRH
model (14). However, other mechanisms independent
of Notch and ephrin signalling might be involved in the
pathogenesis of NRH because of other causes (i.e.
thrombosis).
There are several reports of NRH developing in
response to various drugs such as azathioprine,
6-thioguanine, busulfan or oxaliplatin (10, 37, 38). In
a study by Rubbia-Brandt and colleagues, NRH was
found to be induced by injury to the liver endothe-
lium through oxaliplatin in patients with colorectal









Δ Notch, Δephrins in liver sinusoidal endothelium
Vascular remodelling and sinusoidal capillarization




Fig. 5. Schematic summary of findings in NRH based on current
analysis in humans and in an established murine model: Different
aetiologies can lead to dysregulation of genes in the liver sinusoidal
endothelium (i.e. Notch, ephrins). Changes in endothelial gene
expression induce vascular remodelling and capillarization of the
sinusoidal circulation. In response to vascular remodelling,
hepatocytes proliferate, which leads to nodular transformation of
the liver parenchyma mediated by an unknown mitogenic stimulus
and/or hypoxia. A subgroup of NRH patients can develop portal
hypertension during the course of disease.
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able to reveal a protective effect of bevacizumab, an
antibody against vascular endothelial growth factor
(VEGF). NRH was present in 67 out of 274 patients
treated with oxaliplatin. If oxaliplatin was combined
with bevacizumab, the incidence of grade 3 NRH was
reduced from 28.9% to 11.4%. Azathioprine is the
prevalently documented drug associated with NRH
(9). In previous in vitro experiments, azathioprine was
found to be more toxic to sinusoidal endothelial cells
than to hepatocytes, further supporting that NRH
arises from endothelial damage (39). Using isolated
primary human LSEC incubated with azathioprine, we
have reproduced our in vivo findings and showed that
azathioprine induces the same set of endothelial genes
found in liver biopsies from NRH patients and in the
murine NRH model. These results and the above
mentioned studies strongly favour the concept of
NRH being caused by a circulatory impairment at the
sinusoidal level (12).
In the western world, NRH is the main cause of
non-cirrhotic portal hypertension (5, 6). By analysing a
needle biopsy cohort of 51 NRH patients, we have
identified a correlation between presence of portal
hypertension and disease severity. So far, the relation-
ship between grade of nodularity and increased portal
pressure has not been assessed. Nonetheless, one must
keep in mind that because of the retrospective nature of
this study imaging and/or endoscopy reports were not
available for 14 patients (27.5%), leading to a potential
underestimation of portal hypertension in this analysis.
In conclusion, this finding suggests that patients with
severe nodularity should be assessed for the presence of
portal hypertension.
Interestingly, we observed capillarization demon-
strated by immunohistochemistry in some cases of
advanced grading and/or presence of portal hyperten-
sion, whereas patients with grade 1 nodularity never
showed increased CD34 positivity. However, these find-
ings have limitations. Although NRH is a diffuse liver
disease, nodular transformation can be distributed in an
irregular fashion leading to sampling error. Therefore,
specimen size is crucial for accurate diagnosis and grad-
ing as lesions may be missed if the sample size is too
small (40, 41).
In summary, the present findings establish a corre-
lation between histological grading and the presence
of portal hypertension and provide new insights into
the molecular biology of NRH. This is the first human
study linking LSEC signalling to the pathogenesis of
NRH. Although different aetiologic factors have been
associated with NRH, our results indicate that the
underlying mechanism in these conditions seems to
be an endotheliopathy mediated through the com-
mon final pathway of Dll4/Notch1 and ephrinB2/
EphB4 signalling. Further studies are needed to under-
stand how the multiple conditions associated with
NRH affect the signalling in liver sinusoidal endothe-
lial cells.
Acknowledgements
The authors thank Ursula D€urm€uller for excellent tech-
nical assistance.
Financial support: SNF Score Grant 32323B_123815
to D.S.
Conflict of interest: None.
References
1. Steiner PE. Nodular regenerative hyperplasia of the liver.
The American journal of pathology 1959; 35: 943–53.
2. Wanless IR. Micronodular transformation (nodular
regenerative hyperplasia) of the liver: a report of 64 cases
among 2,500 autopsies and a new classification of benign
hepatocellular nodules. Hepatology 1990; 11: 787–97.
3. Terminology of nodular hepatocellular lesions. Interna-
tional Working Party. Hepatology 1995; 22: 983–93.
4. Arvanitaki M, Adler M. Nodular regenerative hyperplasia
of the liver A review of 14 cases. Hepatogastroenterology
2001; 48: 1425–9.
5. Naber AH, Van Haelst U, Yap SH. Nodular regenerative
hyperplasia of the liver: an important cause of portal
hypertension in non-cirrhotic patients. J Hepatol 1991; 12:
94–9.
6. Al-Mukhaizeem KA, Rosenberg A, Sherker AH. Nodular
regenerative hyperplasia of the liver: an under-recognized
cause of portal hypertension in hematological disorders.
Am J Hematol 2004; 75: 225–30.
7. Hillaire S, Bonte E, Denninger MH, et al. Idiopathic non-
cirrhotic intrahepatic portal hypertension in the West: a
re-evaluation in 28 patients. Gut 2002; 51: 275–80.
8. Stromeyer FW, Ishak KG. Nodular transformation (nodu-
lar “regenerative” hyperplasia) of the liver A clinicopatho-
logic study of 30 cases. Hum Pathol 1981; 12: 60–71.
9. Reshamwala PA, Kleiner DE, Heller T. Nodular regenera-
tive hyperplasia: not all nodules are created equal. Hepa-
tology 2006; 44: 7–14.
10. Seiderer J, Zech CJ, Diebold J, et al. Nodular regenerative
hyperplasia: a reversible entity associated with azathio-
prine therapy. Eur J Gastroenterol Hepatol 2006; 18: 553–5.
11. DeLeve LD. Hepatic microvasculature in liver injury.
Semin Liver Dis 2007; 27: 390–400.
12. Rubbia-Brandt L, Lauwers GY, Wang H, et al. Sinusoidal
obstruction syndrome and nodular regenerative hyperpla-
sia are frequent oxaliplatin-associated liver lesions and
partially prevented by bevacizumab in patients with
hepatic colorectal metastasis. Histopathology 2010; 56:
430–9.
13. Croquelois A, Blindenbacher A, Terracciano L, et al.
Inducible inactivation of Notch1 causes nodular regenera-
tive hyperplasia in mice. Hepatology 2005; 41: 487–96.
14. Dill MT, Rothweiler S, Djonov V, et al. Disruption of
Notch1 Induces Vascular Remodeling, Intussusceptive
Angiogenesis, and Angiosarcomas in Livers of Mice.
Gastroenterology 2012; 142: 967–77.
15. Colina F, Alberti N, Solis JA, et al. Diffuse nodular regen-
erative hyperplasia of the liver (DNRH) A clinicopatho-
logic study of 24 cases. Liver 1989; 9: 253–65.
16. Malamut G, Ziol M, Suarez F, et al. Nodular regenerative
hyperplasia: the main liver disease in patients with primary
hypogammaglobulinemia and hepatic abnormalities.
J Hepatol 2008; 48: 74–82.
Liver International (2013)
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd 9
Rothweiler et al. Notch/Ephrin signalling in patients with NRH
17. Pusztaszeri MP, Seelentag W, Bosman FT. Immunohisto-
chemical expression of endothelial markers CD31, CD34,
von Willebrand factor, and Fli-1 in normal human tissues.
J Histochem Cytochem 2006; 54: 385–95.
18. Kim CK, Lim JH, Park CK, et al. Neoangiogenesis and
sinusoidal capillarization in hepatocellular carcinoma:
correlation between dynamic CT and density of tumor
microvessels. Radiology 2005; 237: 529–34.
19. Makin A, Silverman SH, Lip GY. Peripheral vascular
disease and Virchow’s triad for thrombogenesis. QJM
2002; 95: 199–210.
20. Blendis LM, Lovell D, Barnes CG, et al. Oesophageal vari-
ceal bleeding in Felty’s syndrome associated with nodular
regenerative hyperplasia. Ann Rheum Dis 1978; 37: 183–6.
21. Nakanuma Y, Ohta G, Sasaki K. Nodular regenerative
hyperplasia of the liver associated with polyarteritis nod-
osa. Arch Pathol Lab Med 1984; 108: 133–5.
22. Reynolds WJ, Wanless IR. Nodular regenerative hyperpla-
sia of the liver in a patient with rheumatoid vasculitis: a
morphometric study suggesting a role for hepatic arteritis
in the pathogenesis. J Rheumatol 1984; 11: 838–42.
23. Khalid SK, Garcia-Tsao G. Hepatic vascular malforma-
tions in hereditary hemorrhagic telangiectasia. Semin Liver
Dis 2008; 28: 247–58.
24. Sainson RC, Aoto J, Nakatsu MN, et al. Cell-autonomous
notch signaling regulates endothelial cell branching and
proliferation during vascular tubulogenesis. Faseb J 2005;
19: 1027–9.
25. Noseda M, Chang L, McLean G, et al. Notch activation
induces endothelial cell cycle arrest and participates in
contact inhibition: role of p21Cip1 repression. Mol Cell
Biol 2004; 24: 8813–22.
26. Li X, Zhang X, Leathers R, et al. Notch3 signaling
promotes the development of pulmonary arterial hyper-
tension. Nat Med 2009; 15: 1289–97.
27. Herbert SP, Stainier DY. Molecular control of endothelial
cell behaviour during blood vessel morphogenesis. Nat
Rev Mol Cell Biol 2011; 12: 551–64.
28. Gridley T. Notch signaling in the vasculature. Curr Top
Dev Biol 2010; 92: 277–309.
29. Grego-Bessa J, Luna-Zurita L, Del Monte G, et al. Notch
signaling is essential for ventricular chamber development.
Dev Cell 2007; 12: 415–29.
30. Wang HU, Chen ZF, Anderson DJ. Molecular distinction
and angiogenic interaction between embryonic arteries
and veins revealed by ephrin-B2 and its receptor Eph-B4.
Cell 1998; 93: 741–53.
31. Herbert SP, Huisken J, Kim TN, et al. Arterial-venous seg-
regation by selective cell sprouting: an alternative mode of
blood vessel formation. Science 2009; 326: 294–8.
32. Semela D, Das A, Langer D, et al. Platelet-derived growth
factor signaling through ephrin-b2 regulates hepatic
vascular structure and function. Gastroenterology 2008;
135: 671–9.
33. Krebs LT, Starling C, Chervonsky AV, et al. Notch1 acti-
vation in mice causes arteriovenous malformations pheno-
copied by ephrinB2 and EphB4 mutants. Genesis 2010; 48:
146–50.
34. Carlson TR, Yan Y, Wu X, et al. Endothelial expression of
constitutively active Notch4 elicits reversible arteriovenous
malformations in adult mice. Proc Natl Acad Sci USA
2005; 102: 9884–9.
35. Zhang J, Fukuhara S, Sako K, et al. Angiopoietin-1/Tie2
signal augments basal Notch signal controlling vascular
quiescence by inducing delta-like 4 expression through
AKT-mediated activation of beta-catenin. J Biol Chem
2011; 286: 8055–66.
36. Jeansson M, Gawlik A, Anderson G, et al. Angiopoietin-1
is essential in mouse vasculature during development and
in response to injury. J Clin Investig 2011; 121: 2278–89.
37. Teml A, Schwab M, Hommes DW, et al. A systematic sur-
vey evaluating 6-thioguanine-related hepatotoxicity in
patients with inflammatory bowel disease. Wien Klin
Wochenschr 2007; 119: 519–26.
38. Key NS, Kelly PM, Emerson PM, et al. Oesophageal vari-
ces associated with busulphan-thioguanine combination
therapy for chronic myeloid leukaemia. Lancet 1987; 2:
1050–2.
39. DeLeve LD, Wang X, Kuhlenkamp JF, et al. Toxicity of
azathioprine and monocrotaline in murine sinusoidal
endothelial cells and hepatocytes: the role of glutathione
and relevance to hepatic venoocclusive disease. Hepatology
1996; 23: 589–99.
40. Harris M, Rash RM, Dymock IW. Nodular, non-cirrhotic
liver associated with portal hypertension in a patient with
rheumatoid arthritis. J Clin Pathol 1974; 27: 963–6.
41. Rougier P, Degott C, Rueff B, et al. Nodular regenerative
hyperplasia of the liver Report of six cases and review of
the literature. Gastroenterology 1978; 75: 169–72.
Supporting information
Additional Supporting Information may be found in the
online version of this article:
Table S1. Detailed characteristics of NRH patients
used for gene expression analysis.
Table S2. Primer sequences used for real-time
RT-PCR analysis.
Liver International (2013)
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd10
Notch/Ephrin signalling in patients with NRH Rothweiler et al.
Supplementary Table 1. Detailed characteristics of NRH patients used for gene expression analysis 
  Nodularity NRH risk factor Sex Ethnicity Age at Biopsy Presence of portal hypertension (signs) 
 
3 no m Caucasian 62 yes (varices, splenomegaly,  gastropathy) 
 
2 MGUS m Caucasian 62 no 
 
2 CML leukemia m Caucasian 33 no 
 
2 AMA antibody f Caucasian 35 no 
 
2 no m Caucasian 42 yes (HVPG: 13 mmHg, varices, splenomegaly) 
 
1 no m Caucasian 56 no 
 
1 no f Caucasian 25 no 
 
1 no m Caucasian 41 no 
 
1 no m Asian 49 no 
 
1 no f Caucasian 68 no 
 
1 no m Caucasian 55 no 
 
1 no f Caucasian 63 no 
 
1 no m Caucasian 39 no 
 1 no m Caucasian 35 no 
 




Supplementary Table 2. Primer sequences used for real-time RT-PCR analysis 
   
Gene Forward primer sequence Reverse primer sequence 
Rpl19 5’-GATGCCGGAAAAACACCTTG-3’ 5’-TGGCTGTACCCTTCCGCTT-3’ 
Notch1 5'-CTGCATGCGGCTGTGTCT-3' 5'-GGCTCGGTTCCGGATCA-3' 
Hes1 5'-AAAGATAGCTCGCGGCATTC-3' 5'-AGGTGCTTCACTGTCATTTCCA-3' 
Efnb2 5’-TGCCAGACAAGAGCCATGAA-3’  5’-TGATCCAGCAGAACTTGCATCT-3’ 
EphB4 5’-TTGGAAACTGCTGATCTGAAGTG-3’  5’-CCAGGCCGCTCAGTTCCT-3’ 
Dll4 5'-CCAACTGCCCTTCAATTTCAC-3' 5'-TGCCAAGCTTCGATGATGAG-3' 
TEK 5'-CCAAACGTGATTGACACTGG-3' 5'-TGTGAAGCGTCTCACAGGTC-3' 	
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5. Discussion 
5.1 The role of Notch1 signaling in liver sinusoidal endothelial 
cells 	
  
Endothelial cells display remarkable heterogeneity in cell morphology, function, gene 
expression, and antigen constitution [3,183]. Depending on space and time, the 
endothelium is equipped with appropriate features to meet the demands in different 
organs. In case of the liver, the endothelial cells lining the sinusoids have acquired a 
highly specialized phenotype defined by non-diaphragmed fenestrae, clathrin-coated pits 
and absence of an underlying basement membrane. It has been shown that VEGF plays 
an important role in the generation and maintenance of LSEC fenestration [184]. Deeper 
insights in mechanisms regulating the LSEC phenotype were provided by DeLeve and 
colleagues who identified that VEGF mediated autocrine NO production by sinusoidal 
endothelial cells is required to maintain the sinusoidal endothelium differentiated [39]. In 
this study we analyzed the ultrastructure of the liver microcirculation in conditional Notch1 
KO mice by scanning electron microscopy. We found dramatic changes of the hepatic 
microcirculation affecting the sinusoidal architecture and the LSEC fine structure. On the 
one hand we could show that loss of Notch1 induces vascular remodeling through 
intussusceptive angiogenesis with increased branching and enlarged vessel diameters. 
On the other hand, disruption of Notch1 signaling led to modification of the LSEC porosity 
pattern. The number of fenestrae and sieve plates was drastically decreased, while the 
few remaining fenestrae displayed an increased diameter. Overall, the sinusoidal porosity 
was reduced and some segments of the sinusoids were entirely lined by non-fenestrated 
endothelium resembling a continuous capillary appearance. As it is known that the Notch 
pathway acts downstream of VEGF, it could be speculated that Notch is part of the 
signaling axis responsible for fenestrae regulation in LSEC as a molecular mediator 
conveying the VEGF signal to the actin cytoskeleton. 
 
The effects of Notch signaling are context-dependent: Notch pathway components 
display distinct distribution patterns in the different organs, tissues, and cell types by 
which cell fate decisions can be regulated. To define cell fate specifications, Notch 
intertwines with other signaling pathways. One of them is the Eph/ephrin pathway. The 
arterial marker EphrinB2 is a known downstream target of Notch signaling [168]. 
EphrinB2 and its ligand EphB4 are involved in the embryonic arterial and venous 
endothelial cell specification and their specific expression extends into adulthood to 
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control tissue homeostasis [185]. In isolated LSEC of our Notch1 KO mice, we showed a 
reduced expression of EphrinB2. Finding EphrinB2 expression in LSEC challenges the 
idea that capillaries have neither an arterial nor a venous identity. However, not much is 
known about molecular mechanisms regulating the phenotype of the hepatic sinusoidal 
vasculature. According to our findings, EphrinB2 seems to play a role in the sinusoidal 
circulation. But still, the expression pattern of endothelial markers in hepatic capillaries 
distinguishing them from capillaries in other vascular beds is not completely elucidated 
yet. What becomes clear by finding this interaction of the Notch pathway with other 
signaling pathways is that the liver capillary bed depends not only on one signaling axis, 
rather on a complex vertical and horizontal interplay of several signal transduction 
pathways possibly involving cross-talk between LSEC and neighboring cells. 
 
The vasculature in the adult is normally quiescent and endothelial cells have a low 
proliferation rate. The average turnover time of normal endothelium is more than 1 year 
[183,186]. By looking at our data we found increased LSEC proliferation in livers of 
Notch1 KO mice, which evidences that disruption of Notch1 signaling promotes LSEC 
activation. To ultimately conclude on the role of Notch1 signaling in liver sinusoidal 
endothelial cells the key experiment would be to perform an inducible deletion of Notch1 
specifically in the LSEC population. In our study we performed a global, tissue-unspecific 
Notch1 deletion as well as a specific deletion in the liver epithelial compartment as a 
control. Mice with a hepatocyte-specific Notch1 KO did not have an endothelial response 
or resemble features of nodular regenerative hyperplasia. However, this approach is not 
sufficient to cleanly rule out the possibility that deletion of Notch1 in other non-hepatocyte 
or non-endothelial cell lineages contributes to the development of the observed 
phenotype in MxCre mediated Notch1 deletion. It would be very interesting to see 
whether specific loss of Notch1 in the endothelium only is sufficient to reproduce the 
phenotype observed after global knockout. We tried this approach by crossing the floxed 
Notch1 mice with the VE-cadherin-Cre-ERT2 (provided by L. Iruela-Arispe) mice, but we 
did not achieve a sufficient recombination in the liver endothelium. It has been reported 
that in adults the expression of VE-cadherin is weak in the vasculature of the liver, which 
might be the explanation why we did not observe the NRH phenotype after conditional 
deletion of Notch1 in endothelial cells [187,188]. To circumvent these limitations we 
isolated the three major liver cell populations; hepatocytes, liver sinusoidal endothelial 
cells, and hepatic stellate cells. By assessing the gene expression of several mitogens 
and growth factor receptors upon Notch1 deletion in the different cell types, we could 
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show that there are no major changes in non-endothelial cells, but expression changes of 
endothelial molecules in liver sinusoidal endothelial cells. Thus, we conclude that 
disruption of Notch1 signaling in liver sinusoidal endothelial cells is responsible for the 
observed phenotypic changes in the MxCre Notch1 KO mouse model. With this 
conclusion our study provides a novel hint in unveiling the significance of the Notch1 
signaling pathway in the maintenance of LSEC quiescence and differentiation.  
 
5.2 Endotheliopathy - common feature in nodular regenerative 
hyperplasia and contributor to portal hypertension 	
  
Besides loss of fenestrae we also observed upregulation of CD31, which is absent in 
differentiated LSEC [189]. Both processes demonstrate capillarization of LSEC induced 
by Notch1 deletion. Capillarization has been described in other pathologic states of the 
liver such as fibrosis, hepatitis, alcoholic liver injury, and in the physiological process of 
aging [40,43,45,190–193]. Therefore it becomes clear that injury of an intact endothelium 
is involved in the development of numerous diseases in the liver as well as in other 
organs. Truly, in our experimental approach we observed an increase in the portal 
pressure, which is later on followed by hepatic parenchyma transformation leading to 
NRH. Most commonly, portal hypertension is caused by liver cirrhosis and hepatic fibrosis 
[194]. However, in our animal model we could exclude both of these conditions. We 
hypothesize that the increased portal pressure is due to an increased intrahepatic 
resistance, as the consequence of vascular remodeling at the level of the hepatic 
microcirculation. Determinants of resistance to blood flow are vessel diameter, 
organization of the vascular network, viscosity of the blood, and mechanical forces acting 
on the vessels [195]. Based on physical arguments, the structural alterations (increased 
vessel diameter and increased branching) in our system result in elevation of the blood 
flow resistance in turn leading to portal hypertension. 
Nodular transformation of the liver parenchyma occurred after the increased portal 
pressure was established. To explain the increased hepatocyte proliferation we 
investigated several hepatocyte growth factors (i.e. HGF, TGF-beta, FGF, VEGF), but 
none of them showed an altered expression that would account for the augmented 
hepatoctye proliferation. It remains an open question which stimulus drives the 
regenerative hepatic nodule formation. However, based on our findings we believe that 
hepatocyte proliferation is a secondary adaption in consequence of hemodynamic 
changes induced by vascular remodeling. 
Discussion                   62 
5.3 Translational study: confirming findings from the animal 
model in patients with nodular regenerative hyperplasia 	
  
In the western world, NRH is the main cause of non-cirrhotic portal hypertension [58,196]. 
By analyzing the largest needle biopsy cohort of NRH patients we have identified a 
correlation between presence of portal hypertension and disease severity. So far the 
relationship between grade of nodularity and increased portal pressure has not been 
assessed. According to this correlation we suggest that patients presenting with severe 
nodularity should be assessed for presence of portal hypertension. 
 
A large body of evidence based on multiple case reports indicates that NRH is the result 
of a heterogeneous hepatic blood supply possibly initiated by vascular obliteration. In 
1856, the pathologist Rudolf Virchow postulated that thrombus formation is causally 
related to abnormalities in blood flow (stasis), hypercoagulability of the blood, and 
endothelial injury [197]. In keeping with Virchow’s concept all three categories can be 
involved in the pathogenesis of NRH by causing impaired hepatic blood flow. Vascular 
obstruction can occur at the level of the microvasculature or the portal vein. In the 
literature, there are many cases describing NRH in association with vascular disorders 
such as Felty’s syndrome [198], polyarteritis nodosa [199], rheumatoid vasculitis [200], or 
hereditary hemorrhagic telangiectasia (also known as Osler-Weber-Rendu disease) 
[201], all supporting the idea that vessel lesions are a trigger to commence impaired 
hepatic blood flow. We support the idea that NRH is the expression of a vascular 
pathology at the level of the hepatic microvasculature founded on our results obtained 
from the Notch1 KO animal study. One aim of this translational study was to confirm 
these recent findings in human patients. And indeed, we could show the relevance of the 
same set of genes, identified in mice, in patients diagnosed with NRH. 
 
Literature on the molecular mechanism underlying the pathogenesis of NRH is sparse. In 
our NRH mouse model we could identify Notch1, Dll4, EphrinB2, and Tek as key players 
driving the vascular changes that eventually lead to development of NRH. Gene 
expression analysis in 14 NRH patients confirmed a downregulation of the same set of 
genes. To ensure that expression differences are exclusive for NRH, adequate control 
groups were diligently chosen: HCV patients with no inflammation and no fibrosis referred 
to as “control” group; patients with cirrhosis and focal nodular hyperplasia (FNH) patients 
were selected as two additional control groups showing liver conditions associated with 
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vascular changes. Notch1 showed an overall downregulation in patients with NRH, FNH 
and cirrhosis when compared to controls.  Strikingly, expression of Dll4 and EphrinB2 
was specifically reduced in NRH patients only. The discovery of such a restricted gene 
expression pattern was very surprising to us since the analyzed NRH patients present 
different etiologic factors but somehow the underlying cause in all the patients can be 
attributed to an endotheliopathy mediated through the common final pathway of 
Notch1/Dll4 and EphrinB2/EphB4 signaling. 
 
Not only different diseases were reported to be associated with NRH, but also a number 
of drugs are known to generate NRH. In this context it is worth to mention the recent 
study by Rubbia-Brandt and colleagues, where NRH was found to be induced by injury to 
the liver endothelium through oxaliplatin in patients with colorectal carcinoma. Among 274 
patients treated with Oxaliplatin, NRH was observed in 24.5%. Interestingly, when 
Oxaliplatin was combined with Bevacizumab (an anti-VEGF antibody) less patients 
developed NRH indicating a protective effect of bevacizumab. A possible explanation for 
the positive effect of bevacizumab on oxaliplatin-associated liver injury is the attenuation 
of VEGF-induced upregulation of MMP in sinusoidal endothelial cells. It has been shown 
previously that increased MMP activity permits dehiscence of LSEC from the space of 
Disse, ultimately leading to sinusoidal obstruction [30]. This report therefore corroborates 
the theory of NRH being caused by a circulatory impairment at the level of sinusoids. 
Al-Hamoudi and colleagues, who reported a case of NRH in association with a florid 
carcinoid syndrome, provide further evidence for this hypothesis. Signs of a vasculopathy 
were not present in this case. The authors speculated that NRH is induced by 
microcirculatory disturbances, which are the consequence of vasoactive hormones 
including Serotonin secreted by the tumor [202]. 
 
5.4 Notch1 functions as a tumor-suppressor in the liver 
vasculature 	
  
Given the pleiotropic functions of the highly conserved Notch signaling pathway during 
embryonic development and in adult tissues, it is not surprising that Notch signaling is 
deregulated in many cancers. In view of the necessity of extensive fine-tuning to ensure 
the adequate Notch signal in the appropriate cellular context, aberrant Notch signaling is 
predestined to be implicated in cancer. Similar to its diverse physiologic functions, the 
Notch pathway has been described as a double-edged sword in tumorigenesis with 
oncogenic as well as oncosuppressive activity. 
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The first evidence for a putative role of Notch in cancer derived from the analysis of T-cell 
acute lymphoblastic leukemia (T-ALL) that identified a chromosomal translocation within 
the Notch1 locus [203]. Later, the oncogenic potential of aberrant Notch signaling was 
described in mouse mammary tumor virus (MMTV)-induced breast cancer [204]. As a 
retrovirus, MMTV is able to insert its viral genome in the host genome, thereby 
deregulating the expression of adjacent genes. The Notch4 locus was identified as a 
common integration site of MMTV resulting in the expression of a truncated constitutively 
active Notch4 [157,205]. Over the last years, an oncogenic function of Notch has been 
established in various human malignancies, such as leukemia, breast cancer, colorectal 
cancer, pancreatic cancer, and melanoma [150]. However, there is growing evidence that 
Notch is associated with oncosuppressive roles as observed in hematopoietic cells, skin, 
pancreatic epithelium, and in hepatocytes [206]. These data indicate that Notch signaling 
in cancer has two faces: depending on the cellular context Notch functions either as an 
oncoprotein or as a tumor suppressor. 
 
The data derived from our Notch1 KO mouse model reveal a tumor suppressive role for 
Notch1 signaling in the liver. In our model, we observed activation of liver sinusoidal 
endothelial cells with persistent proliferation, dedifferentiation, and eventually malignant 
transformation. Fifty weeks after Notch1 deletion we found spontaneous development of 
hepatic angiosarcoma with a penetrance of 86%. Therefore, our findings establish Notch1 
as a tumor suppressor gene in the liver endothelium. This conclusion is in line with our 
hypothesis that Notch1 signaling controls tissue homeostasis and vascular quiescence by 
growth suppression. Other groups have also identified Notch pathway components 
implicated in the development of vascular tumors. Treatment with a Dll4-specific 
neutralizing antibody in mice, rats, and cynomolgus monkeys resulted in liver 
histopathology, including centrilobular hepatocyte atrophy, sinusoidal dilation, and bile 
duct proliferation. But only in rats blocking of Dll4-mediated Notch signaling induced 
vascular neoplasms [207]. In a genetic mouse model endothelial specific deletion of Dll4 
caused hepatic vascular lesions, which recapitulated the observed vascular alterations 
evoked by pharmacological inhibition of Dll4/Notch signaling [208]. Continuing the 
investigations of Notch signaling in cancer, Liu et al. had the objective to determine 
whether Notch1 has a tumor suppressor activity. Using an elegant genetic approach, 
where Notch1 loss of heterozygosity is coupled to the level of Notch1 activation, they 
could demonstrate that loss of Notch1 promotes development of vascular tumors, which 
were most prevalent in the liver [180]. These findings reflect a tumor suppressor function 
of Notch1 in the vascular system, further highlighting the importance of Notch1 signaling 
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in liver endothelial cells [180]. In summary, these results suggest an essential role of 
Dll4/Notch1 signaling for maintaining integrity and quiescence of liver sinusoidal 
endothelium and define a tumor suppressor function of the Dll4/Notch1 signaling axis in 
the liver endothelium.  
 
Angiosarcoma is a rare cancer deriving from malignant endothelial cells. It represents a 
highly aggressive tumor with metastasis and dismal prognosis [209]. The molecular 
events implicated in the transformation of differentiated endothelial cells into vascular 
malignancies are poorly understood. These gaps in knowledge impede the development 
of novel treatment strategies, which are urgently needed since treatment options for this 
type of cancer are limited and of transient efficiency [210]. In light of this unfavorable 
situation, in ongoing experiments we aim to dissect the molecular mechanisms driving 
angiosarcoma growth as well as to test anti-angiogenic drugs for the treatment of 
angiosarcoma. In support of an oncosuppressive role of Notch1 in angiosarcoma the 
Notch pathway might provide a novel therapeutic target in angiosarcomas. 
 
5.5 Concluding remarks 	
  
The importance of the Notch pathway in vascular development and arterial-fate 
specification has drawn great attention to this signaling network in vascular cells. For this 
reason, the understanding of the Notch gene regulatory network in the vascular growth, 
function, and maintenance has greatly evolved. Nevertheless, the function of Notch1 in 
the liver remains poorly understood. In this study, we show that Notch1 signaling has the 
capacity to promote homeostasis of the hepatic microvasculature by maintaining LSEC in 
a quiescent and differentiated stage. Loss of Notch1 signaling leads to activation of LSEC 
followed by vascular remodeling, which subsequently causes development of nodular 
regenerative hyperplasia and portal hypertension with the final result of endothelial cell 
tumor. Analyzing liver biopsy samples we provide first insights into the molecular 
pathomechanisms of human NRH by linking the deregulation of endothelial pathways to 
the pathogenesis of NRH. Our research contributes to a better understanding of Notch1 
signaling in the hepatic microcirculation and adds another piece to the evolving picture of 
the Notch signaling pathway. 
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